INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2001, 21717, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2002, 21735, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2003, 21754, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2004, 21756, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2005, 21767, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2006, 21768, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2007, 21769, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2008, 21836, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2009, 22609, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2010, 22881, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2011, 24258, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2012, 24259, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2013, 28607, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2014, 28608, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2015, 29825, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2016, 31862, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2017, 33460, 'Levocetirizine', 'Urinary Retention', 'Urinary retention has been reported postmarketing in patients using levocetirizine.  Caution is advised in patients with predisposing factors of urinary retention such as patients with prostatic hyperplasia, or spinal cord lesions.', '2', '"Product Information. Xyzal (levocetirizine)." UCB Pharma Inc  (2007):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2018, 0, 'Levoleucovorin', 'Seizures', 'Levoleucovorin is the levo isomeric form of racemic d,l-leucovorin, present as the calcium salt.  Seizures and/or syncope have been reported rarely in cancer patients receiving d,l-leucovorin, usually in association with fluoropyrimidine administration, and most commonly in those with CNS metastases or other predisposing factors.  Care is recommended when using this agent in patient with seizure disorders or at risk of seizures even though a causal relationship has not been established.', '2', '"Product Information. Levoleucovorin (levoleucovorin)." Spectrum Chemical  (2008):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2019, 6309, 'Levodopa', 'Heart Diseases', 'Cardiac irregularities occur infrequently in patients on dopamine agonists.  The initial administration and titration is recommended to occur under close cardiac monitoring in a facility equipped for intensive cardiac care.  Adverse cardiac affects may include palpitation, sinus tachycardia, ventricular tachycardia, extrasystole, atrial flutter or fibrillation, or block of AV conduction.', '3', 'Shah PK, Amin DK, Horn E "Adverse clinical and hemodynamic effects of oral levodopa in chronic  congestive heart failure." Am Heart J 110 (1985):  488-9|Benaim ME "Levodopa and arrhythmias." Br Med J 4 (1972):  50-1|Broderick G, Rajfer SI "The use of levodopa, an oral dopamine precursor, in congestive heart  failure." Basic Res Cardiol 84 (1989):  187-90|Chamsi-Pasha H, Horsley M, Barnes PC "Levodopa and congestive cardiomyopathy." Br J Hosp Med 41 (1989):  489|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2020, 10850, 'Levodopa', 'Heart Diseases', 'Cardiac irregularities occur infrequently in patients on dopamine agonists.  The initial administration and titration is recommended to occur under close cardiac monitoring in a facility equipped for intensive cardiac care.  Adverse cardiac affects may include palpitation, sinus tachycardia, ventricular tachycardia, extrasystole, atrial flutter or fibrillation, or block of AV conduction.', '3', 'Shah PK, Amin DK, Horn E "Adverse clinical and hemodynamic effects of oral levodopa in chronic  congestive heart failure." Am Heart J 110 (1985):  488-9|Benaim ME "Levodopa and arrhythmias." Br Med J 4 (1972):  50-1|Broderick G, Rajfer SI "The use of levodopa, an oral dopamine precursor, in congestive heart  failure." Basic Res Cardiol 84 (1989):  187-90|Chamsi-Pasha H, Horsley M, Barnes PC "Levodopa and congestive cardiomyopathy." Br J Hosp Med 41 (1989):  489|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2021, 27442, 'Levodopa', 'Heart Diseases', 'Cardiac irregularities occur infrequently in patients on dopamine agonists.  The initial administration and titration is recommended to occur under close cardiac monitoring in a facility equipped for intensive cardiac care.  Adverse cardiac affects may include palpitation, sinus tachycardia, ventricular tachycardia, extrasystole, atrial flutter or fibrillation, or block of AV conduction.', '3', 'Shah PK, Amin DK, Horn E "Adverse clinical and hemodynamic effects of oral levodopa in chronic  congestive heart failure." Am Heart J 110 (1985):  488-9|Benaim ME "Levodopa and arrhythmias." Br Med J 4 (1972):  50-1|Broderick G, Rajfer SI "The use of levodopa, an oral dopamine precursor, in congestive heart  failure." Basic Res Cardiol 84 (1989):  187-90|Chamsi-Pasha H, Horsley M, Barnes PC "Levodopa and congestive cardiomyopathy." Br J Hosp Med 41 (1989):  489|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2022, 27443, 'Levodopa', 'Heart Diseases', 'Cardiac irregularities occur infrequently in patients on dopamine agonists.  The initial administration and titration is recommended to occur under close cardiac monitoring in a facility equipped for intensive cardiac care.  Adverse cardiac affects may include palpitation, sinus tachycardia, ventricular tachycardia, extrasystole, atrial flutter or fibrillation, or block of AV conduction.', '3', 'Shah PK, Amin DK, Horn E "Adverse clinical and hemodynamic effects of oral levodopa in chronic  congestive heart failure." Am Heart J 110 (1985):  488-9|Benaim ME "Levodopa and arrhythmias." Br Med J 4 (1972):  50-1|Broderick G, Rajfer SI "The use of levodopa, an oral dopamine precursor, in congestive heart  failure." Basic Res Cardiol 84 (1989):  187-90|Chamsi-Pasha H, Horsley M, Barnes PC "Levodopa and congestive cardiomyopathy." Br J Hosp Med 41 (1989):  489|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2023, 27444, 'Levodopa', 'Heart Diseases', 'Cardiac irregularities occur infrequently in patients on dopamine agonists.  The initial administration and titration is recommended to occur under close cardiac monitoring in a facility equipped for intensive cardiac care.  Adverse cardiac affects may include palpitation, sinus tachycardia, ventricular tachycardia, extrasystole, atrial flutter or fibrillation, or block of AV conduction.', '3', 'Shah PK, Amin DK, Horn E "Adverse clinical and hemodynamic effects of oral levodopa in chronic  congestive heart failure." Am Heart J 110 (1985):  488-9|Benaim ME "Levodopa and arrhythmias." Br Med J 4 (1972):  50-1|Broderick G, Rajfer SI "The use of levodopa, an oral dopamine precursor, in congestive heart  failure." Basic Res Cardiol 84 (1989):  187-90|Chamsi-Pasha H, Horsley M, Barnes PC "Levodopa and congestive cardiomyopathy." Br J Hosp Med 41 (1989):  489|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2024, 30279, 'Levodopa', 'Heart Diseases', 'Cardiac irregularities occur infrequently in patients on dopamine agonists.  The initial administration and titration is recommended to occur under close cardiac monitoring in a facility equipped for intensive cardiac care.  Adverse cardiac affects may include palpitation, sinus tachycardia, ventricular tachycardia, extrasystole, atrial flutter or fibrillation, or block of AV conduction.', '3', 'Shah PK, Amin DK, Horn E "Adverse clinical and hemodynamic effects of oral levodopa in chronic  congestive heart failure." Am Heart J 110 (1985):  488-9|Benaim ME "Levodopa and arrhythmias." Br Med J 4 (1972):  50-1|Broderick G, Rajfer SI "The use of levodopa, an oral dopamine precursor, in congestive heart  failure." Basic Res Cardiol 84 (1989):  187-90|Chamsi-Pasha H, Horsley M, Barnes PC "Levodopa and congestive cardiomyopathy." Br J Hosp Med 41 (1989):  489|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2025, 31402, 'Levodopa', 'Heart Diseases', 'Cardiac irregularities occur infrequently in patients on dopamine agonists.  The initial administration and titration is recommended to occur under close cardiac monitoring in a facility equipped for intensive cardiac care.  Adverse cardiac affects may include palpitation, sinus tachycardia, ventricular tachycardia, extrasystole, atrial flutter or fibrillation, or block of AV conduction.', '3', 'Shah PK, Amin DK, Horn E "Adverse clinical and hemodynamic effects of oral levodopa in chronic  congestive heart failure." Am Heart J 110 (1985):  488-9|Benaim ME "Levodopa and arrhythmias." Br Med J 4 (1972):  50-1|Broderick G, Rajfer SI "The use of levodopa, an oral dopamine precursor, in congestive heart  failure." Basic Res Cardiol 84 (1989):  187-90|Chamsi-Pasha H, Horsley M, Barnes PC "Levodopa and congestive cardiomyopathy." Br J Hosp Med 41 (1989):  489|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2026, 33042, 'Levodopa', 'Heart Diseases', 'Cardiac irregularities occur infrequently in patients on dopamine agonists.  The initial administration and titration is recommended to occur under close cardiac monitoring in a facility equipped for intensive cardiac care.  Adverse cardiac affects may include palpitation, sinus tachycardia, ventricular tachycardia, extrasystole, atrial flutter or fibrillation, or block of AV conduction.', '3', 'Shah PK, Amin DK, Horn E "Adverse clinical and hemodynamic effects of oral levodopa in chronic  congestive heart failure." Am Heart J 110 (1985):  488-9|Benaim ME "Levodopa and arrhythmias." Br Med J 4 (1972):  50-1|Broderick G, Rajfer SI "The use of levodopa, an oral dopamine precursor, in congestive heart  failure." Basic Res Cardiol 84 (1989):  187-90|Chamsi-Pasha H, Horsley M, Barnes PC "Levodopa and congestive cardiomyopathy." Br J Hosp Med 41 (1989):  489|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2027, 6309, 'Levodopa', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2028, 10850, 'Levodopa', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2029, 27442, 'Levodopa', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2030, 27443, 'Levodopa', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2031, 27444, 'Levodopa', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2032, 30279, 'Levodopa', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2033, 31402, 'Levodopa', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2034, 33042, 'Levodopa', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', 'Hoehn MM "Levodopa-induced postural hypotension. Treatment with  fludrocortisone." Arch Neurol 32 (1975):  50-1|Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson''s  disease." Eur Neurol 30 (1990):  194-9|"Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn  (2001):|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):|"Product Information. Requip (ropinirole)." SmithKline Beecham  (2001):|"Product Information. Comtan (entacapone)." Novartis Pharmaceuticals  (2001):|"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA  (2006):|"Product Information. Neupro (rotigotine)." Schwarz Pharma  (2007):|"Product Information. Xadago (safinamide)." US WorldMeds LLC  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2035, 6309, 'Levodopa', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', 'Friedman JH, Feinberg SS, Feldman RG "A neuroleptic malignantlike syndrome due to levodopa therapy  withdrawal." JAMA 254 (1985):  2792-5|Genis D "Neuroleptic malignant syndrome: impaired dopaminergic systems?" Neurology 35 (1985):  1806|Rainer C, Scheinost NA, Lefeber EJ "Neuroleptic malignant syndrome. When levodopa withdrawal is the  cause." Postgrad Med 89 (1991):  175-8,|Gibb WR, Griffith DN "Levodopa withdrawal syndrome identical to neuroleptic malignant  syndrome." Postgrad Med J 62 (1986):  59-60|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2036, 10850, 'Levodopa', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', 'Friedman JH, Feinberg SS, Feldman RG "A neuroleptic malignantlike syndrome due to levodopa therapy  withdrawal." JAMA 254 (1985):  2792-5|Genis D "Neuroleptic malignant syndrome: impaired dopaminergic systems?" Neurology 35 (1985):  1806|Rainer C, Scheinost NA, Lefeber EJ "Neuroleptic malignant syndrome. When levodopa withdrawal is the  cause." Postgrad Med 89 (1991):  175-8,|Gibb WR, Griffith DN "Levodopa withdrawal syndrome identical to neuroleptic malignant  syndrome." Postgrad Med J 62 (1986):  59-60|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2037, 27442, 'Levodopa', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', 'Friedman JH, Feinberg SS, Feldman RG "A neuroleptic malignantlike syndrome due to levodopa therapy  withdrawal." JAMA 254 (1985):  2792-5|Genis D "Neuroleptic malignant syndrome: impaired dopaminergic systems?" Neurology 35 (1985):  1806|Rainer C, Scheinost NA, Lefeber EJ "Neuroleptic malignant syndrome. When levodopa withdrawal is the  cause." Postgrad Med 89 (1991):  175-8,|Gibb WR, Griffith DN "Levodopa withdrawal syndrome identical to neuroleptic malignant  syndrome." Postgrad Med J 62 (1986):  59-60|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2038, 27443, 'Levodopa', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', 'Friedman JH, Feinberg SS, Feldman RG "A neuroleptic malignantlike syndrome due to levodopa therapy  withdrawal." JAMA 254 (1985):  2792-5|Genis D "Neuroleptic malignant syndrome: impaired dopaminergic systems?" Neurology 35 (1985):  1806|Rainer C, Scheinost NA, Lefeber EJ "Neuroleptic malignant syndrome. When levodopa withdrawal is the  cause." Postgrad Med 89 (1991):  175-8,|Gibb WR, Griffith DN "Levodopa withdrawal syndrome identical to neuroleptic malignant  syndrome." Postgrad Med J 62 (1986):  59-60|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2039, 27444, 'Levodopa', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', 'Friedman JH, Feinberg SS, Feldman RG "A neuroleptic malignantlike syndrome due to levodopa therapy  withdrawal." JAMA 254 (1985):  2792-5|Genis D "Neuroleptic malignant syndrome: impaired dopaminergic systems?" Neurology 35 (1985):  1806|Rainer C, Scheinost NA, Lefeber EJ "Neuroleptic malignant syndrome. When levodopa withdrawal is the  cause." Postgrad Med 89 (1991):  175-8,|Gibb WR, Griffith DN "Levodopa withdrawal syndrome identical to neuroleptic malignant  syndrome." Postgrad Med J 62 (1986):  59-60|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2040, 30279, 'Levodopa', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', 'Friedman JH, Feinberg SS, Feldman RG "A neuroleptic malignantlike syndrome due to levodopa therapy  withdrawal." JAMA 254 (1985):  2792-5|Genis D "Neuroleptic malignant syndrome: impaired dopaminergic systems?" Neurology 35 (1985):  1806|Rainer C, Scheinost NA, Lefeber EJ "Neuroleptic malignant syndrome. When levodopa withdrawal is the  cause." Postgrad Med 89 (1991):  175-8,|Gibb WR, Griffith DN "Levodopa withdrawal syndrome identical to neuroleptic malignant  syndrome." Postgrad Med J 62 (1986):  59-60|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2041, 31402, 'Levodopa', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', 'Friedman JH, Feinberg SS, Feldman RG "A neuroleptic malignantlike syndrome due to levodopa therapy  withdrawal." JAMA 254 (1985):  2792-5|Genis D "Neuroleptic malignant syndrome: impaired dopaminergic systems?" Neurology 35 (1985):  1806|Rainer C, Scheinost NA, Lefeber EJ "Neuroleptic malignant syndrome. When levodopa withdrawal is the  cause." Postgrad Med 89 (1991):  175-8,|Gibb WR, Griffith DN "Levodopa withdrawal syndrome identical to neuroleptic malignant  syndrome." Postgrad Med J 62 (1986):  59-60|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2042, 33042, 'Levodopa', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', 'Friedman JH, Feinberg SS, Feldman RG "A neuroleptic malignantlike syndrome due to levodopa therapy  withdrawal." JAMA 254 (1985):  2792-5|Genis D "Neuroleptic malignant syndrome: impaired dopaminergic systems?" Neurology 35 (1985):  1806|Rainer C, Scheinost NA, Lefeber EJ "Neuroleptic malignant syndrome. When levodopa withdrawal is the  cause." Postgrad Med 89 (1991):  175-8,|Gibb WR, Griffith DN "Levodopa withdrawal syndrome identical to neuroleptic malignant  syndrome." Postgrad Med J 62 (1986):  59-60|"Product Information. Mirapex (pramipexole)." Boehringer Ingelheim  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2043, 6309, 'Levodopa', 'Psychotic Disorders', 'The use of dopamine agonists has been associated with psychiatric effects such as hallucinations, psychosis, confusion, anxiety, mania, hypomania, depression, rapid mood cycling, nightmares, and hypersexuality.  Therapy with dopamine agonists should be administered cautiously in psychotic patients and all patients should be carefully observed for development of depression and suicidal tendencies.', '3', 'Ko GN, Leckman JF, Heninger GR "Induction of rapid mood cycling during L-dopa treatment in a bipolar  patient." Am J Psychiatry 138 (1981):  1624-5|Ryback RS, Schwab RS "Manic response to levodopa therapy. Report of a case." N Engl J Med 285 (1971):  788-9|Banerjee AK, Falkai PG, Savidge M "Visual hallucinations in the elderly associated with the use of  levodopa." Postgrad Med J 65 (1989):  358-61|Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D ""Panic attacks" in Parkinson''s disease. A long-term complication of  levodopa therapy." Acta Neurol Scand 87 (1993):  14-8|Nausieda PA, Glantz R, Weber S, Baum R, Klawans HL "Psychiatric complications of levodopa therapy of Parkinson''s disease." Adv Neurol 40 (1984):  271-7|Glantz RH, Bieliauskas L, Paleologos N "Behavioral indicators of hallucinosis in levodopa-treated Parkinson''s  disease." Adv Neurol 45 (1987):  417-20|Friedman JH "The management of the levodopa psychoses." Clin Neuropharmacol 14 (1991):  283-95|Harsch HH, Miller M, Young LD "Induction of mania by L-dopa in a nonbipolar patient." J Clin Psychopharmacol 5 (1985):  338-9|Maricle RA, Nutt JG, Carter JH "Mood and anxiety fluctuation in parkinson''s disease associated with levodopa infusion: preliminary findings." Mov Disord 10 (1995):  329-32|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2044, 10850, 'Levodopa', 'Psychotic Disorders', 'The use of dopamine agonists has been associated with psychiatric effects such as hallucinations, psychosis, confusion, anxiety, mania, hypomania, depression, rapid mood cycling, nightmares, and hypersexuality.  Therapy with dopamine agonists should be administered cautiously in psychotic patients and all patients should be carefully observed for development of depression and suicidal tendencies.', '3', 'Ko GN, Leckman JF, Heninger GR "Induction of rapid mood cycling during L-dopa treatment in a bipolar  patient." Am J Psychiatry 138 (1981):  1624-5|Ryback RS, Schwab RS "Manic response to levodopa therapy. Report of a case." N Engl J Med 285 (1971):  788-9|Banerjee AK, Falkai PG, Savidge M "Visual hallucinations in the elderly associated with the use of  levodopa." Postgrad Med J 65 (1989):  358-61|Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D ""Panic attacks" in Parkinson''s disease. A long-term complication of  levodopa therapy." Acta Neurol Scand 87 (1993):  14-8|Nausieda PA, Glantz R, Weber S, Baum R, Klawans HL "Psychiatric complications of levodopa therapy of Parkinson''s disease." Adv Neurol 40 (1984):  271-7|Glantz RH, Bieliauskas L, Paleologos N "Behavioral indicators of hallucinosis in levodopa-treated Parkinson''s  disease." Adv Neurol 45 (1987):  417-20|Friedman JH "The management of the levodopa psychoses." Clin Neuropharmacol 14 (1991):  283-95|Harsch HH, Miller M, Young LD "Induction of mania by L-dopa in a nonbipolar patient." J Clin Psychopharmacol 5 (1985):  338-9|Maricle RA, Nutt JG, Carter JH "Mood and anxiety fluctuation in parkinson''s disease associated with levodopa infusion: preliminary findings." Mov Disord 10 (1995):  329-32|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2045, 27442, 'Levodopa', 'Psychotic Disorders', 'The use of dopamine agonists has been associated with psychiatric effects such as hallucinations, psychosis, confusion, anxiety, mania, hypomania, depression, rapid mood cycling, nightmares, and hypersexuality.  Therapy with dopamine agonists should be administered cautiously in psychotic patients and all patients should be carefully observed for development of depression and suicidal tendencies.', '3', 'Ko GN, Leckman JF, Heninger GR "Induction of rapid mood cycling during L-dopa treatment in a bipolar  patient." Am J Psychiatry 138 (1981):  1624-5|Ryback RS, Schwab RS "Manic response to levodopa therapy. Report of a case." N Engl J Med 285 (1971):  788-9|Banerjee AK, Falkai PG, Savidge M "Visual hallucinations in the elderly associated with the use of  levodopa." Postgrad Med J 65 (1989):  358-61|Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D ""Panic attacks" in Parkinson''s disease. A long-term complication of  levodopa therapy." Acta Neurol Scand 87 (1993):  14-8|Nausieda PA, Glantz R, Weber S, Baum R, Klawans HL "Psychiatric complications of levodopa therapy of Parkinson''s disease." Adv Neurol 40 (1984):  271-7|Glantz RH, Bieliauskas L, Paleologos N "Behavioral indicators of hallucinosis in levodopa-treated Parkinson''s  disease." Adv Neurol 45 (1987):  417-20|Friedman JH "The management of the levodopa psychoses." Clin Neuropharmacol 14 (1991):  283-95|Harsch HH, Miller M, Young LD "Induction of mania by L-dopa in a nonbipolar patient." J Clin Psychopharmacol 5 (1985):  338-9|Maricle RA, Nutt JG, Carter JH "Mood and anxiety fluctuation in parkinson''s disease associated with levodopa infusion: preliminary findings." Mov Disord 10 (1995):  329-32|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2046, 27443, 'Levodopa', 'Psychotic Disorders', 'The use of dopamine agonists has been associated with psychiatric effects such as hallucinations, psychosis, confusion, anxiety, mania, hypomania, depression, rapid mood cycling, nightmares, and hypersexuality.  Therapy with dopamine agonists should be administered cautiously in psychotic patients and all patients should be carefully observed for development of depression and suicidal tendencies.', '3', 'Ko GN, Leckman JF, Heninger GR "Induction of rapid mood cycling during L-dopa treatment in a bipolar  patient." Am J Psychiatry 138 (1981):  1624-5|Ryback RS, Schwab RS "Manic response to levodopa therapy. Report of a case." N Engl J Med 285 (1971):  788-9|Banerjee AK, Falkai PG, Savidge M "Visual hallucinations in the elderly associated with the use of  levodopa." Postgrad Med J 65 (1989):  358-61|Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D ""Panic attacks" in Parkinson''s disease. A long-term complication of  levodopa therapy." Acta Neurol Scand 87 (1993):  14-8|Nausieda PA, Glantz R, Weber S, Baum R, Klawans HL "Psychiatric complications of levodopa therapy of Parkinson''s disease." Adv Neurol 40 (1984):  271-7|Glantz RH, Bieliauskas L, Paleologos N "Behavioral indicators of hallucinosis in levodopa-treated Parkinson''s  disease." Adv Neurol 45 (1987):  417-20|Friedman JH "The management of the levodopa psychoses." Clin Neuropharmacol 14 (1991):  283-95|Harsch HH, Miller M, Young LD "Induction of mania by L-dopa in a nonbipolar patient." J Clin Psychopharmacol 5 (1985):  338-9|Maricle RA, Nutt JG, Carter JH "Mood and anxiety fluctuation in parkinson''s disease associated with levodopa infusion: preliminary findings." Mov Disord 10 (1995):  329-32|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2047, 27444, 'Levodopa', 'Psychotic Disorders', 'The use of dopamine agonists has been associated with psychiatric effects such as hallucinations, psychosis, confusion, anxiety, mania, hypomania, depression, rapid mood cycling, nightmares, and hypersexuality.  Therapy with dopamine agonists should be administered cautiously in psychotic patients and all patients should be carefully observed for development of depression and suicidal tendencies.', '3', 'Ko GN, Leckman JF, Heninger GR "Induction of rapid mood cycling during L-dopa treatment in a bipolar  patient." Am J Psychiatry 138 (1981):  1624-5|Ryback RS, Schwab RS "Manic response to levodopa therapy. Report of a case." N Engl J Med 285 (1971):  788-9|Banerjee AK, Falkai PG, Savidge M "Visual hallucinations in the elderly associated with the use of  levodopa." Postgrad Med J 65 (1989):  358-61|Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D ""Panic attacks" in Parkinson''s disease. A long-term complication of  levodopa therapy." Acta Neurol Scand 87 (1993):  14-8|Nausieda PA, Glantz R, Weber S, Baum R, Klawans HL "Psychiatric complications of levodopa therapy of Parkinson''s disease." Adv Neurol 40 (1984):  271-7|Glantz RH, Bieliauskas L, Paleologos N "Behavioral indicators of hallucinosis in levodopa-treated Parkinson''s  disease." Adv Neurol 45 (1987):  417-20|Friedman JH "The management of the levodopa psychoses." Clin Neuropharmacol 14 (1991):  283-95|Harsch HH, Miller M, Young LD "Induction of mania by L-dopa in a nonbipolar patient." J Clin Psychopharmacol 5 (1985):  338-9|Maricle RA, Nutt JG, Carter JH "Mood and anxiety fluctuation in parkinson''s disease associated with levodopa infusion: preliminary findings." Mov Disord 10 (1995):  329-32|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2048, 30279, 'Levodopa', 'Psychotic Disorders', 'The use of dopamine agonists has been associated with psychiatric effects such as hallucinations, psychosis, confusion, anxiety, mania, hypomania, depression, rapid mood cycling, nightmares, and hypersexuality.  Therapy with dopamine agonists should be administered cautiously in psychotic patients and all patients should be carefully observed for development of depression and suicidal tendencies.', '3', 'Ko GN, Leckman JF, Heninger GR "Induction of rapid mood cycling during L-dopa treatment in a bipolar  patient." Am J Psychiatry 138 (1981):  1624-5|Ryback RS, Schwab RS "Manic response to levodopa therapy. Report of a case." N Engl J Med 285 (1971):  788-9|Banerjee AK, Falkai PG, Savidge M "Visual hallucinations in the elderly associated with the use of  levodopa." Postgrad Med J 65 (1989):  358-61|Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D ""Panic attacks" in Parkinson''s disease. A long-term complication of  levodopa therapy." Acta Neurol Scand 87 (1993):  14-8|Nausieda PA, Glantz R, Weber S, Baum R, Klawans HL "Psychiatric complications of levodopa therapy of Parkinson''s disease." Adv Neurol 40 (1984):  271-7|Glantz RH, Bieliauskas L, Paleologos N "Behavioral indicators of hallucinosis in levodopa-treated Parkinson''s  disease." Adv Neurol 45 (1987):  417-20|Friedman JH "The management of the levodopa psychoses." Clin Neuropharmacol 14 (1991):  283-95|Harsch HH, Miller M, Young LD "Induction of mania by L-dopa in a nonbipolar patient." J Clin Psychopharmacol 5 (1985):  338-9|Maricle RA, Nutt JG, Carter JH "Mood and anxiety fluctuation in parkinson''s disease associated with levodopa infusion: preliminary findings." Mov Disord 10 (1995):  329-32|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2049, 31402, 'Levodopa', 'Psychotic Disorders', 'The use of dopamine agonists has been associated with psychiatric effects such as hallucinations, psychosis, confusion, anxiety, mania, hypomania, depression, rapid mood cycling, nightmares, and hypersexuality.  Therapy with dopamine agonists should be administered cautiously in psychotic patients and all patients should be carefully observed for development of depression and suicidal tendencies.', '3', 'Ko GN, Leckman JF, Heninger GR "Induction of rapid mood cycling during L-dopa treatment in a bipolar  patient." Am J Psychiatry 138 (1981):  1624-5|Ryback RS, Schwab RS "Manic response to levodopa therapy. Report of a case." N Engl J Med 285 (1971):  788-9|Banerjee AK, Falkai PG, Savidge M "Visual hallucinations in the elderly associated with the use of  levodopa." Postgrad Med J 65 (1989):  358-61|Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D ""Panic attacks" in Parkinson''s disease. A long-term complication of  levodopa therapy." Acta Neurol Scand 87 (1993):  14-8|Nausieda PA, Glantz R, Weber S, Baum R, Klawans HL "Psychiatric complications of levodopa therapy of Parkinson''s disease." Adv Neurol 40 (1984):  271-7|Glantz RH, Bieliauskas L, Paleologos N "Behavioral indicators of hallucinosis in levodopa-treated Parkinson''s  disease." Adv Neurol 45 (1987):  417-20|Friedman JH "The management of the levodopa psychoses." Clin Neuropharmacol 14 (1991):  283-95|Harsch HH, Miller M, Young LD "Induction of mania by L-dopa in a nonbipolar patient." J Clin Psychopharmacol 5 (1985):  338-9|Maricle RA, Nutt JG, Carter JH "Mood and anxiety fluctuation in parkinson''s disease associated with levodopa infusion: preliminary findings." Mov Disord 10 (1995):  329-32|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2050, 33042, 'Levodopa', 'Psychotic Disorders', 'The use of dopamine agonists has been associated with psychiatric effects such as hallucinations, psychosis, confusion, anxiety, mania, hypomania, depression, rapid mood cycling, nightmares, and hypersexuality.  Therapy with dopamine agonists should be administered cautiously in psychotic patients and all patients should be carefully observed for development of depression and suicidal tendencies.', '3', 'Ko GN, Leckman JF, Heninger GR "Induction of rapid mood cycling during L-dopa treatment in a bipolar  patient." Am J Psychiatry 138 (1981):  1624-5|Ryback RS, Schwab RS "Manic response to levodopa therapy. Report of a case." N Engl J Med 285 (1971):  788-9|Banerjee AK, Falkai PG, Savidge M "Visual hallucinations in the elderly associated with the use of  levodopa." Postgrad Med J 65 (1989):  358-61|Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, Garcia-Urra D ""Panic attacks" in Parkinson''s disease. A long-term complication of  levodopa therapy." Acta Neurol Scand 87 (1993):  14-8|Nausieda PA, Glantz R, Weber S, Baum R, Klawans HL "Psychiatric complications of levodopa therapy of Parkinson''s disease." Adv Neurol 40 (1984):  271-7|Glantz RH, Bieliauskas L, Paleologos N "Behavioral indicators of hallucinosis in levodopa-treated Parkinson''s  disease." Adv Neurol 45 (1987):  417-20|Friedman JH "The management of the levodopa psychoses." Clin Neuropharmacol 14 (1991):  283-95|Harsch HH, Miller M, Young LD "Induction of mania by L-dopa in a nonbipolar patient." J Clin Psychopharmacol 5 (1985):  338-9|Maricle RA, Nutt JG, Carter JH "Mood and anxiety fluctuation in parkinson''s disease associated with levodopa infusion: preliminary findings." Mov Disord 10 (1995):  329-32|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2051, 6309, 'Levodopa', 'Glaucoma', 'The use of levodopa is contraindicated in patients with acute closed-angle glaucoma.  Levodopa (with or without carbidopa)  may be used in patients with open-angle glaucoma who are receiving appropriate therapy.', '3', '"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2052, 10850, 'Levodopa', 'Glaucoma', 'The use of levodopa is contraindicated in patients with acute closed-angle glaucoma.  Levodopa (with or without carbidopa)  may be used in patients with open-angle glaucoma who are receiving appropriate therapy.', '3', '"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2053, 27442, 'Levodopa', 'Glaucoma', 'The use of levodopa is contraindicated in patients with acute closed-angle glaucoma.  Levodopa (with or without carbidopa)  may be used in patients with open-angle glaucoma who are receiving appropriate therapy.', '3', '"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2054, 27443, 'Levodopa', 'Glaucoma', 'The use of levodopa is contraindicated in patients with acute closed-angle glaucoma.  Levodopa (with or without carbidopa)  may be used in patients with open-angle glaucoma who are receiving appropriate therapy.', '3', '"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2055, 27444, 'Levodopa', 'Glaucoma', 'The use of levodopa is contraindicated in patients with acute closed-angle glaucoma.  Levodopa (with or without carbidopa)  may be used in patients with open-angle glaucoma who are receiving appropriate therapy.', '3', '"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2056, 30279, 'Levodopa', 'Glaucoma', 'The use of levodopa is contraindicated in patients with acute closed-angle glaucoma.  Levodopa (with or without carbidopa)  may be used in patients with open-angle glaucoma who are receiving appropriate therapy.', '3', '"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2057, 31402, 'Levodopa', 'Glaucoma', 'The use of levodopa is contraindicated in patients with acute closed-angle glaucoma.  Levodopa (with or without carbidopa)  may be used in patients with open-angle glaucoma who are receiving appropriate therapy.', '3', '"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2058, 33042, 'Levodopa', 'Glaucoma', 'The use of levodopa is contraindicated in patients with acute closed-angle glaucoma.  Levodopa (with or without carbidopa)  may be used in patients with open-angle glaucoma who are receiving appropriate therapy.', '3', '"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2059, 6309, 'Levodopa', 'Liver Diseases', 'The pharmacokinetics of levodopa have not been studied in patients with hepatic or renal impairment.  Therapy with levodopa should be administered cautiously in patients with liver or disease.  Periodic monitoring of hepatic and renal function is recommended during extended therapy.', '3', '"Product Information. Inbrija (levodopa)." Acorda Therapeutics  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2060, 10850, 'Levodopa', 'Liver Diseases', 'The pharmacokinetics of levodopa have not been studied in patients with hepatic or renal impairment.  Therapy with levodopa should be administered cautiously in patients with liver or disease.  Periodic monitoring of hepatic and renal function is recommended during extended therapy.', '3', '"Product Information. Inbrija (levodopa)." Acorda Therapeutics  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2061, 27442, 'Levodopa', 'Liver Diseases', 'The pharmacokinetics of levodopa have not been studied in patients with hepatic or renal impairment.  Therapy with levodopa should be administered cautiously in patients with liver or disease.  Periodic monitoring of hepatic and renal function is recommended during extended therapy.', '3', '"Product Information. Inbrija (levodopa)." Acorda Therapeutics  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2062, 27443, 'Levodopa', 'Liver Diseases', 'The pharmacokinetics of levodopa have not been studied in patients with hepatic or renal impairment.  Therapy with levodopa should be administered cautiously in patients with liver or disease.  Periodic monitoring of hepatic and renal function is recommended during extended therapy.', '3', '"Product Information. Inbrija (levodopa)." Acorda Therapeutics  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2063, 27444, 'Levodopa', 'Liver Diseases', 'The pharmacokinetics of levodopa have not been studied in patients with hepatic or renal impairment.  Therapy with levodopa should be administered cautiously in patients with liver or disease.  Periodic monitoring of hepatic and renal function is recommended during extended therapy.', '3', '"Product Information. Inbrija (levodopa)." Acorda Therapeutics  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2064, 30279, 'Levodopa', 'Liver Diseases', 'The pharmacokinetics of levodopa have not been studied in patients with hepatic or renal impairment.  Therapy with levodopa should be administered cautiously in patients with liver or disease.  Periodic monitoring of hepatic and renal function is recommended during extended therapy.', '3', '"Product Information. Inbrija (levodopa)." Acorda Therapeutics  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2065, 31402, 'Levodopa', 'Liver Diseases', 'The pharmacokinetics of levodopa have not been studied in patients with hepatic or renal impairment.  Therapy with levodopa should be administered cautiously in patients with liver or disease.  Periodic monitoring of hepatic and renal function is recommended during extended therapy.', '3', '"Product Information. Inbrija (levodopa)." Acorda Therapeutics  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2066, 33042, 'Levodopa', 'Liver Diseases', 'The pharmacokinetics of levodopa have not been studied in patients with hepatic or renal impairment.  Therapy with levodopa should be administered cautiously in patients with liver or disease.  Periodic monitoring of hepatic and renal function is recommended during extended therapy.', '3', '"Product Information. Inbrija (levodopa)." Acorda Therapeutics  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2067, 6309, 'Levodopa', 'Melanoma', 'The use of levodopa is considered by manufacturers to be contraindicated in patients with a history of melanoma or in patients with suspicious, undiagnosed skin lesions.  Levodopa reportedly may activate malignant melanoma, although some investigators have found a causal relationship to be tenuous.', '3', 'Kochar AS "Development of malignant melanoma after levodopa therapy for  Parkinson''s disease. Report of a case and review of the literature." Am J Med 79 (1985):  119-21|Bernstein JE, Medenica M, Soltani K, Solomon A, Lorincz AL "Levodopa administration and multiple primary cutaneous melanomas." Arch Dermatol 116 (1980):  1041-44|Robinson E, Wajsbort J, Hirshowitz B "Levodopa and malignant melanoma." Arch Pathol 95 (1973):  213|Haider SA, Thaller VT "Lid melanoma and parkinsonism." Br J Ophthalmol 76 (1992):  246-7|Gurney H, Coates A, Kefford R "The use of L-dopa and carbidopa in metastatic malignant melanoma." J Invest Dermatol 96 (1991):  85-7|Abramson DH, Rubenfeld MR "Choroidal melanoma and levodopa" JAMA 252 (1984):  1011-2|Fermaglich J, Delaney P "Levodopa and melanoma" JAMA 241 (1979):  883-4|Sober AJ, Wick MM "Levodopa therapy and malignant melanoma." JAMA 240 (1978):  554-5|Rosin MA, Braun M, 3d  Braun M "Malignant melanoma and levodopa." Cutis 33 (1984):  572-4|Fermaglich J, Delaney P "Parkinson''s disease, melanoma, and levodopa." J Neurol 215 (1977):  221-4|Van Rens GH, De Jong PT, Demols EE, Brihaye-Van Geertruyden MF "Uveal malignant melanoma and levodopa therapy in Parkinson''s disease." Ophthalmology 89 (1982):  1464-6|Weiner WJ, Singer C, Sanchez-Ramos JR, Goldenberg JN "Levodopa, melanoma, and Parkinson''s disease." Neurology 43 (1993):  674-7|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2068, 10850, 'Levodopa', 'Melanoma', 'The use of levodopa is considered by manufacturers to be contraindicated in patients with a history of melanoma or in patients with suspicious, undiagnosed skin lesions.  Levodopa reportedly may activate malignant melanoma, although some investigators have found a causal relationship to be tenuous.', '3', 'Kochar AS "Development of malignant melanoma after levodopa therapy for  Parkinson''s disease. Report of a case and review of the literature." Am J Med 79 (1985):  119-21|Bernstein JE, Medenica M, Soltani K, Solomon A, Lorincz AL "Levodopa administration and multiple primary cutaneous melanomas." Arch Dermatol 116 (1980):  1041-44|Robinson E, Wajsbort J, Hirshowitz B "Levodopa and malignant melanoma." Arch Pathol 95 (1973):  213|Haider SA, Thaller VT "Lid melanoma and parkinsonism." Br J Ophthalmol 76 (1992):  246-7|Gurney H, Coates A, Kefford R "The use of L-dopa and carbidopa in metastatic malignant melanoma." J Invest Dermatol 96 (1991):  85-7|Abramson DH, Rubenfeld MR "Choroidal melanoma and levodopa" JAMA 252 (1984):  1011-2|Fermaglich J, Delaney P "Levodopa and melanoma" JAMA 241 (1979):  883-4|Sober AJ, Wick MM "Levodopa therapy and malignant melanoma." JAMA 240 (1978):  554-5|Rosin MA, Braun M, 3d  Braun M "Malignant melanoma and levodopa." Cutis 33 (1984):  572-4|Fermaglich J, Delaney P "Parkinson''s disease, melanoma, and levodopa." J Neurol 215 (1977):  221-4|Van Rens GH, De Jong PT, Demols EE, Brihaye-Van Geertruyden MF "Uveal malignant melanoma and levodopa therapy in Parkinson''s disease." Ophthalmology 89 (1982):  1464-6|Weiner WJ, Singer C, Sanchez-Ramos JR, Goldenberg JN "Levodopa, melanoma, and Parkinson''s disease." Neurology 43 (1993):  674-7|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2069, 27442, 'Levodopa', 'Melanoma', 'The use of levodopa is considered by manufacturers to be contraindicated in patients with a history of melanoma or in patients with suspicious, undiagnosed skin lesions.  Levodopa reportedly may activate malignant melanoma, although some investigators have found a causal relationship to be tenuous.', '3', 'Kochar AS "Development of malignant melanoma after levodopa therapy for  Parkinson''s disease. Report of a case and review of the literature." Am J Med 79 (1985):  119-21|Bernstein JE, Medenica M, Soltani K, Solomon A, Lorincz AL "Levodopa administration and multiple primary cutaneous melanomas." Arch Dermatol 116 (1980):  1041-44|Robinson E, Wajsbort J, Hirshowitz B "Levodopa and malignant melanoma." Arch Pathol 95 (1973):  213|Haider SA, Thaller VT "Lid melanoma and parkinsonism." Br J Ophthalmol 76 (1992):  246-7|Gurney H, Coates A, Kefford R "The use of L-dopa and carbidopa in metastatic malignant melanoma." J Invest Dermatol 96 (1991):  85-7|Abramson DH, Rubenfeld MR "Choroidal melanoma and levodopa" JAMA 252 (1984):  1011-2|Fermaglich J, Delaney P "Levodopa and melanoma" JAMA 241 (1979):  883-4|Sober AJ, Wick MM "Levodopa therapy and malignant melanoma." JAMA 240 (1978):  554-5|Rosin MA, Braun M, 3d  Braun M "Malignant melanoma and levodopa." Cutis 33 (1984):  572-4|Fermaglich J, Delaney P "Parkinson''s disease, melanoma, and levodopa." J Neurol 215 (1977):  221-4|Van Rens GH, De Jong PT, Demols EE, Brihaye-Van Geertruyden MF "Uveal malignant melanoma and levodopa therapy in Parkinson''s disease." Ophthalmology 89 (1982):  1464-6|Weiner WJ, Singer C, Sanchez-Ramos JR, Goldenberg JN "Levodopa, melanoma, and Parkinson''s disease." Neurology 43 (1993):  674-7|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2070, 27443, 'Levodopa', 'Melanoma', 'The use of levodopa is considered by manufacturers to be contraindicated in patients with a history of melanoma or in patients with suspicious, undiagnosed skin lesions.  Levodopa reportedly may activate malignant melanoma, although some investigators have found a causal relationship to be tenuous.', '3', 'Kochar AS "Development of malignant melanoma after levodopa therapy for  Parkinson''s disease. Report of a case and review of the literature." Am J Med 79 (1985):  119-21|Bernstein JE, Medenica M, Soltani K, Solomon A, Lorincz AL "Levodopa administration and multiple primary cutaneous melanomas." Arch Dermatol 116 (1980):  1041-44|Robinson E, Wajsbort J, Hirshowitz B "Levodopa and malignant melanoma." Arch Pathol 95 (1973):  213|Haider SA, Thaller VT "Lid melanoma and parkinsonism." Br J Ophthalmol 76 (1992):  246-7|Gurney H, Coates A, Kefford R "The use of L-dopa and carbidopa in metastatic malignant melanoma." J Invest Dermatol 96 (1991):  85-7|Abramson DH, Rubenfeld MR "Choroidal melanoma and levodopa" JAMA 252 (1984):  1011-2|Fermaglich J, Delaney P "Levodopa and melanoma" JAMA 241 (1979):  883-4|Sober AJ, Wick MM "Levodopa therapy and malignant melanoma." JAMA 240 (1978):  554-5|Rosin MA, Braun M, 3d  Braun M "Malignant melanoma and levodopa." Cutis 33 (1984):  572-4|Fermaglich J, Delaney P "Parkinson''s disease, melanoma, and levodopa." J Neurol 215 (1977):  221-4|Van Rens GH, De Jong PT, Demols EE, Brihaye-Van Geertruyden MF "Uveal malignant melanoma and levodopa therapy in Parkinson''s disease." Ophthalmology 89 (1982):  1464-6|Weiner WJ, Singer C, Sanchez-Ramos JR, Goldenberg JN "Levodopa, melanoma, and Parkinson''s disease." Neurology 43 (1993):  674-7|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2071, 27444, 'Levodopa', 'Melanoma', 'The use of levodopa is considered by manufacturers to be contraindicated in patients with a history of melanoma or in patients with suspicious, undiagnosed skin lesions.  Levodopa reportedly may activate malignant melanoma, although some investigators have found a causal relationship to be tenuous.', '3', 'Kochar AS "Development of malignant melanoma after levodopa therapy for  Parkinson''s disease. Report of a case and review of the literature." Am J Med 79 (1985):  119-21|Bernstein JE, Medenica M, Soltani K, Solomon A, Lorincz AL "Levodopa administration and multiple primary cutaneous melanomas." Arch Dermatol 116 (1980):  1041-44|Robinson E, Wajsbort J, Hirshowitz B "Levodopa and malignant melanoma." Arch Pathol 95 (1973):  213|Haider SA, Thaller VT "Lid melanoma and parkinsonism." Br J Ophthalmol 76 (1992):  246-7|Gurney H, Coates A, Kefford R "The use of L-dopa and carbidopa in metastatic malignant melanoma." J Invest Dermatol 96 (1991):  85-7|Abramson DH, Rubenfeld MR "Choroidal melanoma and levodopa" JAMA 252 (1984):  1011-2|Fermaglich J, Delaney P "Levodopa and melanoma" JAMA 241 (1979):  883-4|Sober AJ, Wick MM "Levodopa therapy and malignant melanoma." JAMA 240 (1978):  554-5|Rosin MA, Braun M, 3d  Braun M "Malignant melanoma and levodopa." Cutis 33 (1984):  572-4|Fermaglich J, Delaney P "Parkinson''s disease, melanoma, and levodopa." J Neurol 215 (1977):  221-4|Van Rens GH, De Jong PT, Demols EE, Brihaye-Van Geertruyden MF "Uveal malignant melanoma and levodopa therapy in Parkinson''s disease." Ophthalmology 89 (1982):  1464-6|Weiner WJ, Singer C, Sanchez-Ramos JR, Goldenberg JN "Levodopa, melanoma, and Parkinson''s disease." Neurology 43 (1993):  674-7|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2072, 30279, 'Levodopa', 'Melanoma', 'The use of levodopa is considered by manufacturers to be contraindicated in patients with a history of melanoma or in patients with suspicious, undiagnosed skin lesions.  Levodopa reportedly may activate malignant melanoma, although some investigators have found a causal relationship to be tenuous.', '3', 'Kochar AS "Development of malignant melanoma after levodopa therapy for  Parkinson''s disease. Report of a case and review of the literature." Am J Med 79 (1985):  119-21|Bernstein JE, Medenica M, Soltani K, Solomon A, Lorincz AL "Levodopa administration and multiple primary cutaneous melanomas." Arch Dermatol 116 (1980):  1041-44|Robinson E, Wajsbort J, Hirshowitz B "Levodopa and malignant melanoma." Arch Pathol 95 (1973):  213|Haider SA, Thaller VT "Lid melanoma and parkinsonism." Br J Ophthalmol 76 (1992):  246-7|Gurney H, Coates A, Kefford R "The use of L-dopa and carbidopa in metastatic malignant melanoma." J Invest Dermatol 96 (1991):  85-7|Abramson DH, Rubenfeld MR "Choroidal melanoma and levodopa" JAMA 252 (1984):  1011-2|Fermaglich J, Delaney P "Levodopa and melanoma" JAMA 241 (1979):  883-4|Sober AJ, Wick MM "Levodopa therapy and malignant melanoma." JAMA 240 (1978):  554-5|Rosin MA, Braun M, 3d  Braun M "Malignant melanoma and levodopa." Cutis 33 (1984):  572-4|Fermaglich J, Delaney P "Parkinson''s disease, melanoma, and levodopa." J Neurol 215 (1977):  221-4|Van Rens GH, De Jong PT, Demols EE, Brihaye-Van Geertruyden MF "Uveal malignant melanoma and levodopa therapy in Parkinson''s disease." Ophthalmology 89 (1982):  1464-6|Weiner WJ, Singer C, Sanchez-Ramos JR, Goldenberg JN "Levodopa, melanoma, and Parkinson''s disease." Neurology 43 (1993):  674-7|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2073, 31402, 'Levodopa', 'Melanoma', 'The use of levodopa is considered by manufacturers to be contraindicated in patients with a history of melanoma or in patients with suspicious, undiagnosed skin lesions.  Levodopa reportedly may activate malignant melanoma, although some investigators have found a causal relationship to be tenuous.', '3', 'Kochar AS "Development of malignant melanoma after levodopa therapy for  Parkinson''s disease. Report of a case and review of the literature." Am J Med 79 (1985):  119-21|Bernstein JE, Medenica M, Soltani K, Solomon A, Lorincz AL "Levodopa administration and multiple primary cutaneous melanomas." Arch Dermatol 116 (1980):  1041-44|Robinson E, Wajsbort J, Hirshowitz B "Levodopa and malignant melanoma." Arch Pathol 95 (1973):  213|Haider SA, Thaller VT "Lid melanoma and parkinsonism." Br J Ophthalmol 76 (1992):  246-7|Gurney H, Coates A, Kefford R "The use of L-dopa and carbidopa in metastatic malignant melanoma." J Invest Dermatol 96 (1991):  85-7|Abramson DH, Rubenfeld MR "Choroidal melanoma and levodopa" JAMA 252 (1984):  1011-2|Fermaglich J, Delaney P "Levodopa and melanoma" JAMA 241 (1979):  883-4|Sober AJ, Wick MM "Levodopa therapy and malignant melanoma." JAMA 240 (1978):  554-5|Rosin MA, Braun M, 3d  Braun M "Malignant melanoma and levodopa." Cutis 33 (1984):  572-4|Fermaglich J, Delaney P "Parkinson''s disease, melanoma, and levodopa." J Neurol 215 (1977):  221-4|Van Rens GH, De Jong PT, Demols EE, Brihaye-Van Geertruyden MF "Uveal malignant melanoma and levodopa therapy in Parkinson''s disease." Ophthalmology 89 (1982):  1464-6|Weiner WJ, Singer C, Sanchez-Ramos JR, Goldenberg JN "Levodopa, melanoma, and Parkinson''s disease." Neurology 43 (1993):  674-7|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2074, 33042, 'Levodopa', 'Melanoma', 'The use of levodopa is considered by manufacturers to be contraindicated in patients with a history of melanoma or in patients with suspicious, undiagnosed skin lesions.  Levodopa reportedly may activate malignant melanoma, although some investigators have found a causal relationship to be tenuous.', '3', 'Kochar AS "Development of malignant melanoma after levodopa therapy for  Parkinson''s disease. Report of a case and review of the literature." Am J Med 79 (1985):  119-21|Bernstein JE, Medenica M, Soltani K, Solomon A, Lorincz AL "Levodopa administration and multiple primary cutaneous melanomas." Arch Dermatol 116 (1980):  1041-44|Robinson E, Wajsbort J, Hirshowitz B "Levodopa and malignant melanoma." Arch Pathol 95 (1973):  213|Haider SA, Thaller VT "Lid melanoma and parkinsonism." Br J Ophthalmol 76 (1992):  246-7|Gurney H, Coates A, Kefford R "The use of L-dopa and carbidopa in metastatic malignant melanoma." J Invest Dermatol 96 (1991):  85-7|Abramson DH, Rubenfeld MR "Choroidal melanoma and levodopa" JAMA 252 (1984):  1011-2|Fermaglich J, Delaney P "Levodopa and melanoma" JAMA 241 (1979):  883-4|Sober AJ, Wick MM "Levodopa therapy and malignant melanoma." JAMA 240 (1978):  554-5|Rosin MA, Braun M, 3d  Braun M "Malignant melanoma and levodopa." Cutis 33 (1984):  572-4|Fermaglich J, Delaney P "Parkinson''s disease, melanoma, and levodopa." J Neurol 215 (1977):  221-4|Van Rens GH, De Jong PT, Demols EE, Brihaye-Van Geertruyden MF "Uveal malignant melanoma and levodopa therapy in Parkinson''s disease." Ophthalmology 89 (1982):  1464-6|Weiner WJ, Singer C, Sanchez-Ramos JR, Goldenberg JN "Levodopa, melanoma, and Parkinson''s disease." Neurology 43 (1993):  674-7|"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2075, 6309, 'Levodopa', 'Lung Diseases', 'Because of the risk of bronchospasm, use of levodopa in patients with asthma, COPD, or other chronic underlying lung disease is not recommended.', '3', '"Product Information. Inbrija (levodopa)." Acorda Therapeutics  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2076, 10850, 'Levodopa', 'Lung Diseases', 'Because of the risk of bronchospasm, use of levodopa in patients with asthma, COPD, or other chronic underlying lung disease is not recommended.', '3', '"Product Information. Inbrija (levodopa)." Acorda Therapeutics  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2077, 27442, 'Levodopa', 'Lung Diseases', 'Because of the risk of bronchospasm, use of levodopa in patients with asthma, COPD, or other chronic underlying lung disease is not recommended.', '3', '"Product Information. Inbrija (levodopa)." Acorda Therapeutics  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2078, 27443, 'Levodopa', 'Lung Diseases', 'Because of the risk of bronchospasm, use of levodopa in patients with asthma, COPD, or other chronic underlying lung disease is not recommended.', '3', '"Product Information. Inbrija (levodopa)." Acorda Therapeutics  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2079, 27444, 'Levodopa', 'Lung Diseases', 'Because of the risk of bronchospasm, use of levodopa in patients with asthma, COPD, or other chronic underlying lung disease is not recommended.', '3', '"Product Information. Inbrija (levodopa)." Acorda Therapeutics  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2080, 30279, 'Levodopa', 'Lung Diseases', 'Because of the risk of bronchospasm, use of levodopa in patients with asthma, COPD, or other chronic underlying lung disease is not recommended.', '3', '"Product Information. Inbrija (levodopa)." Acorda Therapeutics  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2081, 31402, 'Levodopa', 'Lung Diseases', 'Because of the risk of bronchospasm, use of levodopa in patients with asthma, COPD, or other chronic underlying lung disease is not recommended.', '3', '"Product Information. Inbrija (levodopa)." Acorda Therapeutics  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2082, 33042, 'Levodopa', 'Lung Diseases', 'Because of the risk of bronchospasm, use of levodopa in patients with asthma, COPD, or other chronic underlying lung disease is not recommended.', '3', '"Product Information. Inbrija (levodopa)." Acorda Therapeutics  (2019):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2083, 6309, 'Levodopa', 'Peptic Ulcer Hemorrhage', 'The use of levodopa, especially in combinations with carbidopa, has been associated with an increase in the frequency of gastrointestinal hemorrhage.  Therapy with levodopa should be administered cautiously in patients with a history of peptic ulcer disease or gastrointestinal hemorrhage.', '2', '"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2084, 10850, 'Levodopa', 'Peptic Ulcer Hemorrhage', 'The use of levodopa, especially in combinations with carbidopa, has been associated with an increase in the frequency of gastrointestinal hemorrhage.  Therapy with levodopa should be administered cautiously in patients with a history of peptic ulcer disease or gastrointestinal hemorrhage.', '2', '"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2085, 27442, 'Levodopa', 'Peptic Ulcer Hemorrhage', 'The use of levodopa, especially in combinations with carbidopa, has been associated with an increase in the frequency of gastrointestinal hemorrhage.  Therapy with levodopa should be administered cautiously in patients with a history of peptic ulcer disease or gastrointestinal hemorrhage.', '2', '"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2086, 27443, 'Levodopa', 'Peptic Ulcer Hemorrhage', 'The use of levodopa, especially in combinations with carbidopa, has been associated with an increase in the frequency of gastrointestinal hemorrhage.  Therapy with levodopa should be administered cautiously in patients with a history of peptic ulcer disease or gastrointestinal hemorrhage.', '2', '"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2087, 27444, 'Levodopa', 'Peptic Ulcer Hemorrhage', 'The use of levodopa, especially in combinations with carbidopa, has been associated with an increase in the frequency of gastrointestinal hemorrhage.  Therapy with levodopa should be administered cautiously in patients with a history of peptic ulcer disease or gastrointestinal hemorrhage.', '2', '"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2088, 30279, 'Levodopa', 'Peptic Ulcer Hemorrhage', 'The use of levodopa, especially in combinations with carbidopa, has been associated with an increase in the frequency of gastrointestinal hemorrhage.  Therapy with levodopa should be administered cautiously in patients with a history of peptic ulcer disease or gastrointestinal hemorrhage.', '2', '"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2089, 31402, 'Levodopa', 'Peptic Ulcer Hemorrhage', 'The use of levodopa, especially in combinations with carbidopa, has been associated with an increase in the frequency of gastrointestinal hemorrhage.  Therapy with levodopa should be administered cautiously in patients with a history of peptic ulcer disease or gastrointestinal hemorrhage.', '2', '"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2090, 33042, 'Levodopa', 'Peptic Ulcer Hemorrhage', 'The use of levodopa, especially in combinations with carbidopa, has been associated with an increase in the frequency of gastrointestinal hemorrhage.  Therapy with levodopa should be administered cautiously in patients with a history of peptic ulcer disease or gastrointestinal hemorrhage.', '2', '"Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):|"Product Information. Sinemet CR (carbidopa-levodopa)." DuPont Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2091, 15058, 'Leucovorin', 'Anemia', 'The use of leucovorin is inappropriate therapy for patients with undiagnosed anemia.  Leucovorin can obscure the diagnosis of pernicious anemia by alleviating the hematologic conditions and allowing progression of neurologic complications.', '3', '"Product Information. Wellcovorin (leucovorin)." Glaxo Wellcome, Research Triangle Park, NC.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2092, 15059, 'Leucovorin', 'Anemia', 'The use of leucovorin is inappropriate therapy for patients with undiagnosed anemia.  Leucovorin can obscure the diagnosis of pernicious anemia by alleviating the hematologic conditions and allowing progression of neurologic complications.', '3', '"Product Information. Wellcovorin (leucovorin)." Glaxo Wellcome, Research Triangle Park, NC.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2093, 15058, 'Leucovorin', 'Peptic Ulcer', 'Leucovorin enhances the toxicity of 5-fluorouracil.  When these drugs are administered concurrently in the palliative therapy of advanced colorectal cancer, gastrointestinal toxicities, particularly stomatitis and diarrhea are observed more commonly and may be more severe and of prolonged duration.  Therapy with these agents must not be initiated or continued in patients who have symptoms of gastrointestinal toxicity of any severity until those symptoms have completely resolved.  Monitor patients experiencing diarrhea and institute appropriate care.', '3', '"Product Information. Wellcovorin (leucovorin)." Glaxo Wellcome, Research Triangle Park, NC.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2094, 15059, 'Leucovorin', 'Peptic Ulcer', 'Leucovorin enhances the toxicity of 5-fluorouracil.  When these drugs are administered concurrently in the palliative therapy of advanced colorectal cancer, gastrointestinal toxicities, particularly stomatitis and diarrhea are observed more commonly and may be more severe and of prolonged duration.  Therapy with these agents must not be initiated or continued in patients who have symptoms of gastrointestinal toxicity of any severity until those symptoms have completely resolved.  Monitor patients experiencing diarrhea and institute appropriate care.', '3', '"Product Information. Wellcovorin (leucovorin)." Glaxo Wellcome, Research Triangle Park, NC.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2095, 15058, 'Leucovorin', 'Kidney Diseases', 'Leucovorin is excreted by the kidney and the risk of toxic reactions to the drug may be greater in patients with impaired renal function.  Leucovorin should be used cautiously on these patients, and care should be taken in dose selection.  Monitoring of renal function is recommended.', '2', '"Product Information. Wellcovorin (leucovorin)." Glaxo Wellcome, Research Triangle Park, NC.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2096, 15059, 'Leucovorin', 'Kidney Diseases', 'Leucovorin is excreted by the kidney and the risk of toxic reactions to the drug may be greater in patients with impaired renal function.  Leucovorin should be used cautiously on these patients, and care should be taken in dose selection.  Monitoring of renal function is recommended.', '2', '"Product Information. Wellcovorin (leucovorin)." Glaxo Wellcome, Research Triangle Park, NC.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2097, 15058, 'Leucovorin', 'Seizures', 'Seizures have occurred rarely during administration of leucovorin, primarily in patients receiving high dose leucovorin or leucovorin in combination with 5-fluorouracil, or in patients with a history of seizures or central nervous system abnormalities (unspecified).  Folic acid in large amounts may counter the anticonvulsant effects of phenobarbital, phenytoin, and pimozide.  Clinical monitoring of seizure activity is recommended and modification of anticonvulsant therapy may be necessary.', '2', '"Product Information. Wellcovorin (leucovorin)." Glaxo Wellcome, Research Triangle Park, NC.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2098, 15059, 'Leucovorin', 'Seizures', 'Seizures have occurred rarely during administration of leucovorin, primarily in patients receiving high dose leucovorin or leucovorin in combination with 5-fluorouracil, or in patients with a history of seizures or central nervous system abnormalities (unspecified).  Folic acid in large amounts may counter the anticonvulsant effects of phenobarbital, phenytoin, and pimozide.  Clinical monitoring of seizure activity is recommended and modification of anticonvulsant therapy may be necessary.', '2', '"Product Information. Wellcovorin (leucovorin)." Glaxo Wellcome, Research Triangle Park, NC.', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2099, 1038, 'Levomefolic acid', 'Bipolar Disorder', 'L-methylfolate should be used with caution in patients with a history of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder since mood elevation in this population is possible.', '2', '"Product Information. L-Methylfolate Calcium (l-methylfolate)." Virtus Pharmaceuticals LLC  (2018):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2100, 326, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2101, 327, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2102, 2863, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2103, 4510, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2104, 4967, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2105, 5022, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2106, 5760, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2107, 6679, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2108, 6918, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2109, 6919, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2110, 7113, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2111, 7172, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2112, 7173, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2113, 7174, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2114, 7175, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2115, 7234, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2116, 7235, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2117, 7236, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2118, 7262, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2119, 7263, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2120, 7264, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2121, 7267, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2122, 7268, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2123, 7271, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2124, 7275, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2125, 7277, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2126, 8000, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2127, 8302, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2128, 11185, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2129, 11201, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2130, 11202, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2131, 11203, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2132, 11204, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2133, 11205, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2134, 11209, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2135, 11210, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2136, 11894, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2137, 12162, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2138, 12163, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2139, 12810, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2140, 13106, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2141, 13430, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2142, 13685, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2143, 15307, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2144, 15308, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2145, 16345, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2146, 17139, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2147, 17140, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2148, 18676, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2149, 21404, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2150, 21405, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2151, 21761, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2152, 21762, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2153, 21764, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2154, 21765, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2155, 21772, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2156, 21773, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2157, 21774, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2158, 21776, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2159, 22464, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2160, 22465, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2161, 22932, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2162, 23178, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2163, 23216, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2164, 25557, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2165, 25920, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2166, 26371, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2167, 27931, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2168, 28717, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2169, 28733, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2170, 28734, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2171, 31459, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2172, 32857, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2173, 33578, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2174, 33889, 'Levofloxacin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2175, 326, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2176, 327, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2177, 2863, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2178, 4510, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2179, 4967, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2180, 5022, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2181, 5760, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2182, 6679, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2183, 6918, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2184, 6919, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2185, 7113, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2186, 7172, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2187, 7173, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2188, 7174, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2189, 7175, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2190, 7234, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2191, 7235, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2192, 7236, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2193, 7262, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2194, 7263, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2195, 7264, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2196, 7267, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2197, 7268, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2198, 7271, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2199, 7275, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2200, 7277, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2201, 8000, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2202, 8302, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2203, 11185, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2204, 11201, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2205, 11202, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2206, 11203, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2207, 11204, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2208, 11205, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2209, 11209, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2210, 11210, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2211, 11894, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2212, 12162, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2213, 12163, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2214, 12810, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2215, 13106, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2216, 13430, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2217, 13685, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2218, 15307, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2219, 15308, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2220, 16345, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2221, 17139, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2222, 17140, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2223, 18676, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2224, 21404, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2225, 21405, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2226, 21761, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2227, 21762, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2228, 21764, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2229, 21765, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2230, 21772, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2231, 21773, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2232, 21774, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2233, 21776, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2234, 22464, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2235, 22465, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2236, 22932, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2237, 23178, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2238, 23216, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2239, 25557, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2240, 25920, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2241, 26371, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2242, 27931, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2243, 28717, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2244, 28733, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2245, 28734, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2246, 31459, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2247, 32857, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2248, 33578, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2249, 33889, 'Levofloxacin', 'Central Nervous System Diseases', 'Quinolones may cause CNS stimulation manifested as tremors, agitation, restlessness, anxiety, confusion, hallucinations, paranoia, insomnia, toxic psychosis, and/or seizures.  Benign intracranial hypertension has also been reported.  Therapy with quinolones should be administered cautiously in patients with or predisposed to seizures or other CNS abnormalities.  In addition, these patients should be advised to avoid the consumption of caffeine-containing products during therapy with some quinolones, most notably ciprofloxacin, enoxacin, and cinoxacin, since these agents can substantially reduce the clearance of caffeine and other methylxanthines, potentially resulting in severe CNS reactions.', '3', 'Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|Arcieri G, Griffith E, Gruenwaldt G, et al. "A survey of clinical experience with ciprofloxacin, a new quinolone antimicrobial." J Clin Pharmacol 28 (1988):  179-89|McCue JD, Zandt JR "Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole." Am J Med 90 (1991):  528-9|Arcieri G, August R, Becker N, et al. "Clinical experience with ciprofloxacin in the USA." Eur J Clin Microbiol 5 (1986):  220-5|Altes J, Gasco J, De Antonio J, Villalonga C "Ciprofloxacin and delirium." Ann Intern Med 110 (1989):  170-1|McDermott JL, Gideonse N, Campbell JW "Acute delirium associated with ciprofloxacin administration in a hospitalized elderly patient." J Am Geriatr Soc 39 (1991):  909-10|Slavich IL, Gleffe Rf, Haas EJ "Grand mal epileptic seizures during ciprofloxacin therapy." JAMA 261 (1989):  558-9|Moore B, Safani M, Keesey J "Possible exacerbation of myasthenia gravis by ciprofloxacin." Lancet Jan (1988):  882|Semel JD, Allen N "Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole." South Med J 84 (1991):  465-8|Karki SD, Bentley DW, Raghavan M "Seizure with ciprofloxacin and theophylline combined therapy." DICP 24 (1990):  595-6|Schwartz MT, Calvert JF "Potential neurologic toxicity related to ciprofloxacin." Ann Pharmacother 24 (1990):  138-40|Anastasio GD, Menscer D, Little JM "Norfloxacin and seizures." Ann Intern Med 109 (1988):  169-70|Todd PA, Faulds D "Ofloxacin: a reappraisal of its antimicrobial activity, pharmacology, and therapeutic use." Drugs 42 (1991):  825-76|Unseld E, Ziegler G, Gemeinhardt A, Janssen U, Klotz U "Possible interaction of fluoroquinolones with benzodiazepine-GABA-receptorn complex." Br J Clin Pharmacol 30 (1990):  63-70|Fennig S, Mauas L "Ofloxacin-induced delirium." J Clin Psychiatry 53 (1992):  137-8|Tack KJ, Smith JA "The safety profile of ofloxacin." Am J Med 87 (1989):  s78-81|Jaber LA, Bailey EM, Rybak MJ "Enoxacin: a new fluoroquinolone." Clin Pharm 8 (1989):  97-107|Wadworth AN, Goa KL "Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use." Drugs 42 (1991):  1018-60|Bednarczyk EM, Green JA, Nelson D, et al. "Comparative assessment of the effect of lomefloxacin, ciprofloxacin, and placebo on cerebral blood flow, and glucose and oxygen metabolism in healthy subjects by position emission tomography." Pharmacotherapy 12 (1992):  369-75|Poc TE, Marion GS, Jackson DS "Seizures due to nalidixic acid therapy." South Med J 77 (1984):  539-40|Burt RA "Review of adverse reactions associated with cinoxacin and other drugs used to treat urinary tract infections." Urology 23 (1984):  101-7|Norrby SR "Side-effects of quinolones: comparisons between quinolones and other antibiotics." Eur J Clin Microbiol Infect Dis 10 (1991):  378-83|Fraser AG, Harrower AD "Convulsions and hyperglycaemia asociated with nalidixic acid." Br Med J 2 (1977):  1518|Kremer L, Walton M, Wardle EN "Nalidixic acid and intracranial hypertension." Br Med J 4 (1967):  488|Leslie PJ, Cregeen RJ, Proudfoot AT "Lactic acidosis, hyperglycaemia and convulsions following nalidixic acid overdosage." Hum Toxicol 3 (1984):  239-43|Cox CE, Simmons JR "Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy." South Med J 75 (1982):  549-50|Sisca TS, Heel RC, Romankiewicz JA "Cinoxacin. A review of its pharmacological properties and therapeutic efficacy in the treatment of urinary tract infections." Drugs 25 (1983):  544-69|Stamey TA "Cinoxacin: an overview." Urology 17 (1981):  492-5|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Akhtar S, Ahmad H "Ciprofloxacin-induced catatonia." J Clin Psychiatry 54 (1993):  115-6|Isaacson SH, Carr J, Rowan AJ "Ciprofloxacin-induced complex partial status epilepticus manifesting as an acute confusional state." Neurology 43 (1993):  1619-21|Getenet JC, Croisile B, Vighetto A, et al. "Idiopathic intracranial hypertension after ofloxacin treatment." Acta Neurol Scand 87 (1993):  503-4|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Fanhavard P, Sanchorawala V, Oh J, Moser EM, Smith SP "Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures." Ann Pharmacother 28 (1994):  869-72|Rosolen A, Drigo P, Zanesco L "Acute hemiparesis associated with ciprofloxacin." BMJ 309 (1994):  1411|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Winrow AP, Supramaniam G "Benign intracranial hypertension after ciprofloxacin administration." Arch Dis Child 65 (1990):  1165-6|Thomas RJ, Regan DR "Association of a tourette-like syndrome with ofloxacin." Ann Pharmacother 30 (1996):  138-41|Traeger SM, Bonfiglio MF, Wilson JA, Martin BR, Nackes NA "Seizures associated with ofloxacin therapy." Clin Infect Dis 21 (1995):  1504-6|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Ernst ME, Ernst EJ, Klepser ME "Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?" Am J Health Syst Pharm 54 (1997):  2569-84|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Haria M, Lamb HM "Trovafloxacin." Drugs 54 (1997):  435-45;disc. 446|Walton GD, Hon JK, Mulpur TG "Ofloxacin-induced seizure." Ann Pharmacother 31 (1997):  1475-7|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Melvani S, Speed BR "Alatrofloxacin-induced seizures during slow intravenous infusion." Ann Pharmacother 34 (2000):  1017-9|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|De Sarro A, De Sarro G "Adverse reactions to fluoroquinolones. An overview on mechanistic aspects." Curr Med Chem 8 (2001):  371-84|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2250, 326, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2251, 327, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2252, 2863, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2253, 4510, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2254, 4967, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2255, 5022, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2256, 5760, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2257, 6679, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2258, 6918, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2259, 6919, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2260, 7113, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2261, 7172, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2262, 7173, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2263, 7174, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2264, 7175, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2265, 7234, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2266, 7235, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2267, 7236, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2268, 7262, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2269, 7263, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2270, 7264, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2271, 7267, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2272, 7268, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2273, 7271, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2274, 7275, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2275, 7277, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2276, 8000, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2277, 8302, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2278, 11185, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2279, 11201, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2280, 11202, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2281, 11203, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2282, 11204, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2283, 11205, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2284, 11209, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2285, 11210, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2286, 11894, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2287, 12162, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2288, 12163, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2289, 12810, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2290, 13106, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2291, 13430, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2292, 13685, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2293, 15307, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2294, 15308, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2295, 16345, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2296, 17139, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2297, 17140, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2298, 18676, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2299, 21404, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2300, 21405, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2301, 21761, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2302, 21762, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2303, 21764, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2304, 21765, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2305, 21772, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2306, 21773, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2307, 21774, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2308, 21776, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2309, 22464, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2310, 22465, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2311, 22932, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2312, 23178, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2313, 23216, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2314, 25557, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2315, 25920, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2316, 26371, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2317, 27931, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2318, 28717, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2319, 28733, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2320, 28734, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2321, 31459, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2322, 32857, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2323, 33578, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2324, 33889, 'Levofloxacin', 'Myasthenia Gravis', 'Fluoroquinolones have neuromuscular blocking activity and may exacerbate muscle weakness in persons with myasthenia gravis.  Postmarketing serious adverse events, including deaths and requirement for ventilatory support, have been associated with fluoroquinolones use in persons with myasthenia gravis.  Fluoroquinolones should be avoided in patients with history of myasthenia gravis.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2325, 326, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2326, 327, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2327, 2863, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2328, 4510, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2329, 4967, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2330, 5022, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2331, 5760, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2332, 6679, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2333, 6918, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2334, 6919, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2335, 7113, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2336, 7172, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2337, 7173, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2338, 7174, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2339, 7175, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2340, 7234, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2341, 7235, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2342, 7236, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2343, 7262, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2344, 7263, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2345, 7264, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2346, 7267, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2347, 7268, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2348, 7271, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2349, 7275, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2350, 7277, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2351, 8000, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2352, 8302, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2353, 11185, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2354, 11201, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2355, 11202, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2356, 11203, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2357, 11204, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2358, 11205, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2359, 11209, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2360, 11210, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2361, 11894, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2362, 12162, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2363, 12163, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2364, 12810, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2365, 13106, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2366, 13430, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2367, 13685, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2368, 15307, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2369, 15308, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2370, 16345, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2371, 17139, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2372, 17140, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2373, 18676, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2374, 21404, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2375, 21405, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2376, 21761, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2377, 21762, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2378, 21764, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2379, 21765, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2380, 21772, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2381, 21773, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2382, 21774, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2383, 21776, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2384, 22464, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2385, 22465, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2386, 22932, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2387, 23178, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2388, 23216, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2389, 25557, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2390, 25920, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2391, 26371, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2392, 27931, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2393, 28717, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2394, 28733, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2395, 28734, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2396, 31459, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2397, 32857, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2398, 33578, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2399, 33889, 'Levofloxacin', 'Peripheral Nervous System Diseases', 'The use of quinolones has been associated with an increased risk of peripheral neuropathy.  Monitor closely and discontinue their use in patients experiencing symptoms of peripheral neuropathy.  It is recommended to avoid these agents in patients who have previously experienced peripheral neuropathy.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2400, 326, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2401, 327, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2402, 2863, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2403, 4510, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2404, 4967, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2405, 5022, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2406, 5760, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2407, 6679, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2408, 6918, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2409, 6919, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2410, 7113, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2411, 7172, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2412, 7173, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2413, 7174, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2414, 7175, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2415, 7234, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2416, 7235, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2417, 7236, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2418, 7262, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2419, 7263, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2420, 7264, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2421, 7267, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2422, 7268, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2423, 7271, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2424, 7275, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2425, 7277, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2426, 8000, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2427, 8302, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2428, 11185, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2429, 11201, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2430, 11202, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2431, 11203, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2432, 11204, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2433, 11205, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2434, 11209, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2435, 11210, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2436, 11894, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2437, 12162, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2438, 12163, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2439, 12810, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2440, 13106, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2441, 13430, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2442, 13685, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2443, 15307, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2444, 15308, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2445, 16345, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2446, 17139, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2447, 17140, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2448, 18676, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2449, 21404, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2450, 21405, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2451, 21761, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2452, 21762, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2453, 21764, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2454, 21765, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2455, 21772, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2456, 21773, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2457, 21774, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2458, 21776, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2459, 22464, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2460, 22465, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2461, 22932, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2462, 23178, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2463, 23216, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2464, 25557, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2465, 25920, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2466, 26371, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2467, 27931, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2468, 28717, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2469, 28733, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2470, 28734, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2471, 31459, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2472, 32857, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2473, 33578, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2474, 33889, 'Levofloxacin', 'Long QT Syndrome', 'Quinolones have been reported to prolong the QT interval of the electrocardiogram in some patients.  QT prolongation may potentiate the risk of ventricular arrhythmias including ventricular tachycardia, ventricular fibrillation, and torsade de pointes.  The risk appears to be greatest with grepafloxacin and sparfloxacin (both are no longer marketed in the U.S.), although cardiovascular morbidity and mortality attributable to QT prolongation have also been reported rarely with others like gatifloxacin, levofloxacin, ciprofloxacin, and ofloxacin.  Reported cases have primarily occurred in patients with advanced age, cardiac disease, electrolyte disturbances, and/or underlying medical problems for which they were receiving concomitant medications known to prolong the QT interval.  Therapy with quinolones should be avoided in patients with known QT prolongation and/or uncorrected electrolyte disorders (hypokalemia or hypomagnesemia) and in patients treated concomitantly with class IA or III antiarrhythmic agents.  Cautious use with ECG monitoring is advised in patients with other proarrhythmic conditions such as clinically significant bradycardia, congestive heart failure, acute myocardial ischemia, and atrial fibrillation.  As QT prolongation may be a concentration-dependent effect, it is important that the recommended dosages or infusion rates of these drugs not be exceeded, particularly in patients with renal and/or hepatic impairment.', '3', 'Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996):  161-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|Demolis JL, Charransol A, Funck-Brentano C, Jaillon P "Effects of a single oral dose of sparfloxacin on ventricular repolarization in healthy volunteers." Br J Clin Pharmacol 41 (1996):  499-503|Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996):  350-1|Morganroth J, Hunt T, Dorr MB, Magner D, Talbot GH "The cardiac pharmacodynamics of therapeutic doses of sparfloxacin." Clin Ther 21 (1999):  1171-81|Samaha FF "QTC interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin." Am J Med 107 (1999):  528-9|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Siepmann M, Kirch W "Drug points - Tachycardia associated with moxifloxacin." Br Med J 322 (2001):  23|Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001):  301-19|Iannini PB, Circiumaru I "Gatifloxacin-induced QTc prolongation and ventricular tachycardia." Pharmacotherapy 21 (2001):  361-2|Demolis JL, Kubitza D, Tenneze L, Funck-Bretano C "Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects." Clin Pharmacol Ther 68 (2000):  658-66|Iannini PB, Doddamani S, Byazrova E, Curciumaru I, Kramer H "Risk of torsades de pointes with non-cardiac drugs." BMJ 322 (2001):  46-7|Kang J, Wang L, Chen XL, Triggle DJ, Rampe D "Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG." Mol Pharmacol 59 (2001):  122-6|Kahn JB "Latest industry information on the safety profile of levofloxacin in the US." Chemotherapy 47 Suppl 3 (2001):  32-7|Frothingham R "Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin." Pharmacotherapy 21 (2001):  1468-72|Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB "Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors." Clin Infect Dis 34 (2002):  861-3|Oliphant CM, Green GM "Quinolones: a comprehensive review." Am Fam Physician 65 (2002):  455-64|Owens RC Jr, Ambrose PG "Torsades de pointes associated with fluoroquinolones." Pharmacotherapy 22 (2002):  663-8; discussion 668-72|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Noel GJ, Natarajan J, Chien S, Hunt TL, Goodman DB, Abels R "Effects of three fluoroquinolones on QT interval in healthy adults after single doses." Clin Pharmacol Ther 73 (2003):  292-303|Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004):  55-6|Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002):  121-8|Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J "Measuring the Effects of Supratherapeutic Doses of Levofloxacin on Healthy Volunteers Using Four Methods of QT Correction and Periodic and Continuous ECG Recordings." J Clin Pharmacol 44 (2004):  464-73|Owens RC "QT Prolongation with Antimicrobial Agents : Understanding the Significance." Drugs 64 (2004):  1091-124|Daya SK, Gowda RM, Khan IA "Ciprofloxacin- and hypocalcemia-induced torsade de pointes triggered by hemodialysis." Am J Ther 11 (2004):  77-9|Katritsis D, Camm AJ "Quinolones: cardioprotective or cardiotoxic." Pacing Clin Electrophysiol 26 (2003):  2317-20|Stahlmann R "Clinical toxicological aspects of fluoroquinolones." Toxicol Lett 127 (2002):  269-77', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2475, 326, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2476, 327, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2477, 2863, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2478, 4510, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2479, 4967, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2480, 5022, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2481, 5760, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2482, 6679, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2483, 6918, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2484, 6919, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2485, 7113, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2486, 7172, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2487, 7173, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2488, 7174, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2489, 7175, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2490, 7234, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2491, 7235, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2492, 7236, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2493, 7262, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2494, 7263, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2495, 7264, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2496, 7267, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2497, 7268, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2498, 7271, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2499, 7275, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2500, 7277, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2501, 8000, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2502, 8302, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2503, 11185, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2504, 11201, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2505, 11202, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2506, 11203, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2507, 11204, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2508, 11205, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2509, 11209, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2510, 11210, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2511, 11894, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2512, 12162, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2513, 12163, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2514, 12810, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2515, 13106, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2516, 13430, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2517, 13685, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2518, 15307, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2519, 15308, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2520, 16345, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2521, 17139, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2522, 17140, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2523, 18676, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2524, 21404, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2525, 21405, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2526, 21761, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2527, 21762, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2528, 21764, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2529, 21765, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2530, 21772, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2531, 21773, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2532, 21774, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2533, 21776, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2534, 22464, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2535, 22465, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2536, 22932, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2537, 23178, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2538, 23216, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2539, 25557, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2540, 25920, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2541, 26371, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2542, 27931, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2543, 28717, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2544, 28733, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2545, 28734, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2546, 31459, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2547, 32857, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2548, 33578, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2549, 33889, 'Levofloxacin', 'Tendinopathy', 'Tendonitis and ruptures of the shoulder, hand, and Achilles tendons have been reported in patients receiving quinolones, both during and after treatment.  Avoid the use of these agents in patients who have a history of tendon disorders or have experienced tendinitis or tendon rupture.  Therapy with quinolones should be administered cautiously in patients with patients with kidney, heart, and lung transplant, since it may delay the recognition or confound the diagnosis of a quinolone-induced musculoskeletal effect.  Factors that may independently increase the risk of tendon rupture include strenuous physical activity, renal failure, and previous tendon disorders such as rheumatoid arthritis.  It is recommended to discontinue these agents if, at any time during therapy, pain, inflammation or rupture of a tendon develops and institute appropriate treatment.', '3', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Donck JB, Segaert MF, Vanrenterghem YF "Fluoroquinolones and achilles tendinopathy in renal transplant recipients." Transplantation 58 (1994):  736-7|Schacht P, Arcieri G, Hullmann R "Safety of oral ciprofloxacin. An update based on clinical trial results." Am J Med 87 (1989):  s98-102|Zabraniecki L, Negrier I, Vergne P, Arnaud M, Bonnet C, Bertin P, Treves R "Fluoroquinolone induced tendinopathy: report of 6 cases." J Rheumatol 23 (1996):  516-20|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Carrasco JM, Garcia B, Andujar C, Garrote F, de Juana P, Bermejo T "Tendinitis associated with ciprofloxacin." Ann Pharmacother 31 (1997):  120|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|Casparian JM, Luchi M, Moffat RE, Hinthorn D "Quinolones and tendon ruptures." South Med J 93 (2000):  392-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2550, 326, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2551, 327, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2552, 2863, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2553, 4510, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2554, 4967, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2555, 5022, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2556, 5760, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2557, 6679, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2558, 6918, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2559, 6919, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2560, 7113, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2561, 7172, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2562, 7173, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2563, 7174, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2564, 7175, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2565, 7234, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2566, 7235, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2567, 7236, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2568, 7262, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2569, 7263, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2570, 7264, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2571, 7267, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2572, 7268, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2573, 7271, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2574, 7275, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2575, 7277, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2576, 8000, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2577, 8302, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2578, 11185, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2579, 11201, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2580, 11202, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2581, 11203, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2582, 11204, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2583, 11205, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2584, 11209, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2585, 11210, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2586, 11894, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2587, 12162, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2588, 12163, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2589, 12810, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2590, 13106, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2591, 13430, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2592, 13685, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2593, 15307, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2594, 15308, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2595, 16345, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2596, 17139, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2597, 17140, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2598, 18676, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2599, 21404, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2600, 21405, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2601, 21761, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2602, 21762, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2603, 21764, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2604, 21765, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2605, 21772, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2606, 21773, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2607, 21774, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2608, 21776, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2609, 22464, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2610, 22465, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2611, 22932, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2612, 23178, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2613, 23216, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2614, 25557, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2615, 25920, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2616, 26371, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2617, 27931, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2618, 28717, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2619, 28733, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2620, 28734, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2621, 31459, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2622, 32857, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2623, 33578, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2624, 33889, 'Levofloxacin', 'Crystalluria', 'Crystalluria has been reported rarely during quinolone therapy.  Although it is not expected to occur under normal circumstances with usual recommended dosages, patients who are dehydrated (e.g., due to severe diarrhea or vomiting) may be at increased risk and should be encouraged to consume additional amounts of liquid or given intravenous fluid to ensure an adequate urinary output.  Alkalinity of the urine should be avoided, since it may also increase the risk of crystalluria.  Renal function tests should be performed periodically during prolonged therapy (> 2 weeks).', '2', 'Thorsteinsson SB, Bergan T, Oddsdottir S, Rohwedder R, Holm R "Crystalluria and ciprofloxacin, influence of urinary pH and hydration." Chemotherapy 32 (1986):  408-17|Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986):  187-93|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Neggram (nalidixic acid)." Sanofi Winthrop Pharmaceuticals|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Avelox (moxifloxacin)." Bayer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|Stratta P, Lazzarich E, Canavese C, Bozzola C, Monga G "Ciprofloxacin crystal nephropathy." Am J Kidney Dis 50 (2007):  330-5', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2625, 326, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2626, 327, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2627, 2863, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2628, 4510, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2629, 4967, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2630, 5022, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2631, 5760, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2632, 6679, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2633, 6918, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2634, 6919, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2635, 7113, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2636, 7172, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2637, 7173, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2638, 7174, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2639, 7175, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2640, 7234, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2641, 7235, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2642, 7236, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2643, 7262, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2644, 7263, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2645, 7264, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2646, 7267, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2647, 7268, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2648, 7271, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2649, 7275, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2650, 7277, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2651, 8000, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2652, 8302, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2653, 11185, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2654, 11201, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2655, 11202, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2656, 11203, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2657, 11204, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2658, 11205, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2659, 11209, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2660, 11210, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2661, 11894, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2662, 12162, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2663, 12163, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2664, 12810, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2665, 13106, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2666, 13430, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2667, 13685, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2668, 15307, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2669, 15308, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2670, 16345, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2671, 17139, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2672, 17140, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2673, 18676, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2674, 21404, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2675, 21405, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2676, 21761, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2677, 21762, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2678, 21764, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2679, 21765, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2680, 21772, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2681, 21773, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2682, 21774, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2683, 21776, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2684, 22464, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2685, 22465, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2686, 22932, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2687, 23178, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2688, 23216, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2689, 25557, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2690, 25920, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2691, 26371, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2692, 27931, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2693, 28717, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2694, 28733, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2695, 28734, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2696, 31459, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2697, 32857, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2698, 33578, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2699, 33889, 'Levofloxacin', 'Diabetes Mellitus', 'The use of certain quinolones has been associated with disturbances in blood glucose homeostasis possibly stemming from effects on pancreatic beta cell ATP-sensitive potassium channels that regulate insulin secretion.  Hypoglycemia and, less frequently, hyperglycemia have been reported, although the latter may also occur due to infection alone.  Hypoglycemia has usually occurred in patients with diabetes receiving concomitant oral hypoglycemic agents and/or insulin.  Administration of ciprofloxacin, levofloxacin, norfloxacin, and especially gatifloxacin in patients treated with sulfonylureas or other oral hypoglycemic agents has resulted in severe, refractory hypoglycemia and hypoglycemic coma.  Elderly patients and patients with reduced renal function are particularly susceptible.  Blood glucose should be monitored more closely whenever quinolones are prescribed to patients with diabetes.  Gatifloxacin has been known to cause hypoglycemic episodes generally within the first 3 days of therapy and sometimes even after the first dose, while hyperglycemia usually occurs 4 to 10 days after initiation of therapy.  Patients should be counseled to recognize symptoms of hypoglycemia such as headache, dizziness, drowsiness, nausea, tremor, weakness, hunger, excessive perspiration, and palpitations.  If hypo- or hyperglycemia occur during quinolone therapy, patients should initiate appropriate remedial therapy immediately, discontinue the antibiotic, and contact their physician.', '2', '"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Raxar (grepafloxacin)." Glaxo Wellcome  (2001):|"Product Information. Trovan (trovafloxacin)." Pfizer U.S. Pharmaceuticals  (2001):|Gajjar DA, LaCreta FP, Kollia GD, et al. "Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise." Pharmacotherapy 20 (6 Pt 2) (2000):  s76-86|Roberge RJ, Kaplan R, Frank R, Fore C "Glyburide-ciprofloxacin interaction with resistant hypoglycemia." Ann Emerg Med 36 (2000):  160-3|Rubinstein E "History of quinolones and their side effects." Chemotherapy 47 Suppl 3 (2001):  3-8|Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH "Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents." Am J Med 113 (2002):  232-4|Baker SE, Hangii MC "Possible gatifloxacin-induced hypoglycemia." Ann Pharmacother 36 (2002):  1722-6|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):|"Hypoglycemia and hyperglycemia with fluoroquinolones." Med Lett Drugs Ther 45 (2003):  64|Donaldson AR, Vandiver JR, Finch CK "Possible gatifloxacin-induced hyperglycemia." Ann Pharmacother 38 (2004):  602-5|LeBlanc M, Belanger C, Cossette P "Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy." Pharmacotherapy 24 (2004):  926-31|Biggs WS "Hypoglycemia and hyperglycemia associated with gatifloxacin use in elderly patients." J Am Board Fam Pract 16 (2004):  455-7|Gavin JR 3rd, Kubin R, Choudhri S, et al. "Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies." Drug Saf 27 (2004):  671-86|Saraya A, Yokokura M, Gonoi T, Seino S "Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K(+) channels." Eur J Pharmacol 497 (2004):  111-7|Lin G, Hays DP, Spillane L "Refractory hypoglycemia from ciprofloxacin and glyburide interaction." J Toxicol Clin Toxicol 42 (2004):  295-7|Friedrich LV, Dougherty R "Fatal hypoglycemia associated with levofloxacin." Pharmacotherapy 24 (2004):  1807-12|Bhasin R, Arce FC, Pasmantier R "Hypoglycemia associated with the use of gatifloxacin." Am J Med Sci 330 (2005):  250-3|McMorran M, Morrison H, Letourneau G "Gatifloxacin (Tequin): hypoglycemia and hyperglycemia.  http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v13n3_e.html#1"   (2006):|Park-Wyllie LY, Juurlink DN, Kopp A, et al. "Outpatient gatifloxacin therapy and dysglycemia in older adults." N Engl J Med 354 (2006):  1352-61|Wang S, Rizvi AA "Levofloxacin-induced hypoglycemia in a nondiabetic patient." Am J Med Sci 331 (2006):  334-5|Kanbay M, Aydogan T, Bozalan R, et al. "A rare but serious side effect of levofloxacin: hypoglycemia in a geriatric patient." Diabetes Care 29 (2006):  1716-7|Kelesidis T, Canseco E "Quinolone-induced hypoglycemia: a life-threatening but potentially reversible side effect." Am J Med 123 (2010):  e5-6|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2700, 326, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2701, 327, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2702, 2863, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2703, 4510, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2704, 4967, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2705, 5022, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2706, 5760, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2707, 6679, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2708, 6918, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2709, 6919, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2710, 7113, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2711, 7172, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2712, 7173, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2713, 7174, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2714, 7175, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2715, 7234, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2716, 7235, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2717, 7236, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2718, 7262, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2719, 7263, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2720, 7264, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2721, 7267, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2722, 7268, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2723, 7271, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2724, 7275, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2725, 7277, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2726, 8000, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2727, 8302, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2728, 11185, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2729, 11201, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2730, 11202, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2731, 11203, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2732, 11204, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2733, 11205, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2734, 11209, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2735, 11210, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2736, 11894, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2737, 12162, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2738, 12163, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2739, 12810, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2740, 13106, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2741, 13430, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2742, 13685, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2743, 15307, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2744, 15308, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2745, 16345, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2746, 17139, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2747, 17140, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2748, 18676, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2749, 21404, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2750, 21405, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2751, 21761, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2752, 21762, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2753, 21764, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2754, 21765, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2755, 21772, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2756, 21773, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2757, 21774, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2758, 21776, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2759, 22464, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2760, 22465, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2761, 22932, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2762, 23178, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2763, 23216, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2764, 25557, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2765, 25920, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2766, 26371, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2767, 27931, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2768, 28717, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2769, 28733, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2770, 28734, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2771, 31459, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2772, 32857, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2773, 33578, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2774, 33889, 'Levofloxacin', 'Diseases requiring hemodialysis', 'The following quinolones are known to be partially removed by hemodialysis and should be administered after dialysis: ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, and ofloxacin.', '2', 'Singlas E, Taburet AM, Landru I, Albin H, Ryckelinck JP "Pharmacokinetics of ciprofloxacin tablets in renal failure: infuluence of haemodialysis." Eur J Clin Pharmacol 31 (1987):  389-93|Kampf D, Borner K, Pustelnik A "Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients." Eur J Clin Pharmacol 42 (1992):  95-9|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Dorfler A, Schultz W, Burkhardt F, Zichner M "Pharmacokinetics of ofloxacin in patients on haemodialysis treatment." Drugs 34 (1987):  62-70|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Thalhammer F, Kletzmayr J, ElMenyawi I, Kovarik J, Rosenkranz AR, Traunmuller F, Horl WH, Burgmann H "Ofloxacin clearance during hemodialysis: A comparison of polysulfone and cellulose acetate hemodialyzers." Am J Kidney Dis 32 (1998):  642-5|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2775, 326, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2776, 327, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2777, 2863, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2778, 4510, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2779, 4967, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2780, 5022, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2781, 5760, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2782, 6679, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2783, 6918, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2784, 6919, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2785, 7113, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2786, 7172, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2787, 7173, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2788, 7174, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2789, 7175, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2790, 7234, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2791, 7235, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2792, 7236, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2793, 7262, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2794, 7263, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2795, 7264, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2796, 7267, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2797, 7268, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2798, 7271, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2799, 7275, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2800, 7277, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2801, 8000, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2802, 8302, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2803, 11185, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2804, 11201, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2805, 11202, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2806, 11203, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2807, 11204, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2808, 11205, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2809, 11209, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2810, 11210, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2811, 11894, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2812, 12162, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2813, 12163, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2814, 12810, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2815, 13106, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2816, 13430, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2817, 13685, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2818, 15307, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2819, 15308, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2820, 16345, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2821, 17139, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2822, 17140, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2823, 18676, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2824, 21404, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2825, 21405, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2826, 21761, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2827, 21762, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2828, 21764, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2829, 21765, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2830, 21772, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2831, 21773, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2832, 21774, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2833, 21776, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2834, 22464, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2835, 22465, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2836, 22932, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2837, 23178, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2838, 23216, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2839, 25557, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2840, 25920, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2841, 26371, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2842, 27931, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2843, 28717, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2844, 28733, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2845, 28734, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2846, 31459, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2847, 32857, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2848, 33578, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2849, 33889, 'Levofloxacin', 'Kidney Diseases', 'Quinolones (except trovafloxacin, moxifloxacin, and nalidixic acid) and their metabolites are eliminated by the kidney.  Patients with renal impairment may be at greater risk for adverse effects from quinolones, including nephrotoxicity, due to decreased drug clearance.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment and severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during therapy.', '2', 'Boelaert J, Valcke Y, Schurgers M, et al. "The pharmacokinetics of ciprofloxacin in patients with impaired renal function." J Antimicrob Chemother 16 (1985):  87-93|Webb DB, Roberts DE, Williams JD, Asscher AW "Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kindney function." J Antimicrob Chemother 18 (1986):  83-7|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Pharmacokinetic study of ciprofloxacin in patients with impaired renal function." Am J Med 82 (1987):  139-41|Drusano GL, Weir M, Forrest A, Plaisance K, Emm T, Standiford HC "Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function." Antimicrob Agents Chemother 31 (1987):  860-4|Gasser TC, Ebert SC, Graversen PH, Madsen PO "Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function." Antimicrob Agents Chemother 31 (1987):  709-12|Hootkins R, Fenves AZ, Stephens MK "Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature." Clin Nephrol 32 (1989):  75-8|Plaisance KI, Drusano GL, Forrest A, Weir MR, Standiford HC "Effect of renal function on the bioavailability of ciprofloxacin." Antimicrob Agents Chemother 34 (1990):  1031-4|Allon M, Lopez EJ, Min KW "Acute renal failure due to ciprofloxacin." Arch Intern Med 150 (1990):  2187-9|Rastogi S, Atkinson JLD, McCarthy JT "Allergic nephropathy associated with ciprofloxacin." Mayo Clin Proc 65 (1990):  987-9|Helmink R, Benediktsson H "Ciprofloxacin-induced allergic interstitial nephritis." Nephron 55 (1990):  432-3|Simpson J, Watson AR, Mellersh A, Nelson CS, Dodd K "Typhoid fever, ciprofloxacin, and renal failure." Arch Dis Child 66 (1991):  1083-4|Gonski PN "Ciprofloxacin-induced renal failure in an elderly patient." Med J Aust 154 (1991):  638-9|Rippelmeyer DJ, Synhavsky A "Ciprofloxacin and allergic interstitial nephritis." Ann Intern Med 109 (1988):  170|Ying LS, Johnson CA "Ciprofloxacin-induced interstitial nephritis." Clin Pharm 8 (1989):  518-21|Murray KM, Wilson MG "Suspected ciprofloxacin-induced interstitial nephritis." Ann Pharmacother 24 (1990):  379-80|Hatton J, Haagensen D "Renal dysfunction associated with ciprofloxacin." Pharmacotherapy 10 (1990):  337-40|Boelaert J, de Jaegere PP, Daneels R, Schurgers M, Gordts B "Case report of renal failure during norfloxacin therapy." Clin Nephrol 25 (1986):  272|Lameire N, Rosenkranz B, Malerczyk V, Lehr KH, Veys N, Ringoir S "Ofloxacin pharamcokinetics in chronic renal failure and dialysis." Clin Pharmacokinet 21 (1991):  357-71|Fillastre JP, Leroy A, Humbert G "Ofloxacin pharmacokinetics in renal failure." Antimicrob Agents Chemother 31 (1987):  156-60|Nilsen OG, Saltvedt E, Walstad RA, Marstein S "Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function." Am J Med 92 (1992):  s38-40|Van Der Auwera P, Stolear JC, George B, Dudley MN "Pharmacokinetics of enoxacin and its oxometabolite following intravenous administration to patients with different degrees of renal impairment." Antimicrob Agents Chemother 34 (1990):  1491-7|Nix DE, Schultz RW, Frost RW, et al. "The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin." J Antimicrob Chemother 21 (1988):  87-95|Blum RA, Schultz RW, Schentag JJ "Pharmacokinetics of lomefloxacin in renally compromised patients." Antimicrob Agents Chemother 34 (1990):  2364-8|Leroy A, Fillastre JP, Humbert G "Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function." Antimicrob Agents Chemother 34 (1990):  17-20|Lode H, Hoffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P "Comparative pharmacokinetics of new quinolones." Drugs 34 Suppl (1987):  21-5|Eandi M, Viano I, Di Nola F, Leone L, Genazzani E "Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage." Eur J Clin Microbiol 2 (1983):  253-9|Arrigo G, Cavaliere G, D''Amico G, Passarella E, Broccalia G "Pharmacokinetics of norfloxacin in chronic renal failure." Int J Clin Pharmacol Ther Toxicol 23 (1985):  491-6|Fillastre JP, Hannedouche T, Leroy A, Humbert G "Pharmacokinetics of norfloxacin in renal failure." J Antimicrob Chemother 14 (1984):  439|Hughes PJ, Webb DB, Asscher AW "Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function: some preliminary results." J Antimicrob Chemother 13 (1984):  55-7|Alestig K "The pharmacokinetics of oral quinolones (norfloxacin, ciprofloxacin, ofloxacin)." Scand J Infect Dis 68 (1990):  19-22|Bandai H, Tsukabihara Y, Yamoto E, et al. "Pharmacokinetics of ofloxacin in severe chronic renal failure." Clin Ther 11 (1989):  210-18|Ortiz A, Plaza JJ, Egido J "Ciprofloxacin-associated tubulointerstitial nephritis with linear tubular basement membrane deposits." Nephron 60 (1992):  248|Maigaard S, Frimodt-Moller N, Welling PG, Madsen PO "Cinoxacin: pharmacokinetics and tolerance in patients with normal and impaired renal function." Antimicrob Agents Chemother 16 (1979):  411-6|Ohkawa M, Sugata T, Sawaki M, Okasho A, Kuroda K, Yamada H "Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function." J Antimicrob Chemother 8 (1981):  447-51|"Product Information. Cipro (ciprofloxacin)." Bayer  (2002):|"Product Information. Penetrex (enoxacin)." Rhone Poulenc Rorer  (2002):|"Product Information. Maxaquin (lomefloxacin)." Searle  (2002):|"Product Information. Noroxin (norfloxacin)." Merck & Co., Inc  (2001):|"Product Information. Floxin (ofloxacin)." Ortho McNeil Pharmaceutical  (2001):|Just PM "Overview of the fluoroquinolone antibiotics." Pharmacotherapy 13 (1993):  s4-17|Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E "Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD." Clin Nephrol 39 (1993):  53-8|"Product Information. Cinobac (cinoxacin)." Oclassen Pharmaceuticals Inc  (2001):|Anand A "Ciprofloxacin nephrotoxicity." Arch Intern Med 153 (1993):  2705-6|Lucena MI, Marquez M, Velasco JL, Andrade RJ "Acute renal failure attributable to ciprofloxacin in a patient with the acquired immunodeficiency syndrome." Arch Intern Med 155 (1995):  114|Shimada J, Nogita T, Ishibashi Y "Clinical pharmacokinetics of sparfloxacin." Clin Pharmacokinet 25 (1993):  358-69|Fillastre JP, Montay G, Bruno R, Etienne I, Dhib M, Vivier N, Le Roux Y, Guimart C, Gay G, Schott D "Pharmacokinetics of sparfloxacin in patients with renal impairment." Antimicrob Agents Chemother 38 (1994):  733-7|"Product Information. Levaquin (levofloxacin)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Zagam (sparfloxacin)." Rhone Poulenc Rorer  (2001):|"Product Information. Tequin (gatifloxacin)." Bristol-Myers Squibb  (2001):|"Product Information. Factive (gemifloxacin)." *GeneSoft Inc  (2003):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2850, 6693, 'Levomilnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2851, 14737, 'Levomilnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2852, 22757, 'Levomilnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2853, 22758, 'Levomilnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2854, 22759, 'Levomilnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2855, 22760, 'Levomilnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2856, 22761, 'Levomilnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2857, 22762, 'Levomilnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2858, 23184, 'Levomilnacipran', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2859, 6693, 'Levomilnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2860, 14737, 'Levomilnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2861, 22757, 'Levomilnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2862, 22758, 'Levomilnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2863, 22759, 'Levomilnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2864, 22760, 'Levomilnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2865, 22761, 'Levomilnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2866, 22762, 'Levomilnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2867, 23184, 'Levomilnacipran', 'Kidney Diseases', 'The clearance of SNRI antidepressants is decreased in subjects with renal impairment.  SNRIs should be used with caution in this group of patients and a dose adjustment is recommended in those with moderate and severe renal impairment.  The use of SNRIs is not recommended in patients with end-stage renal disease.', '3', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2868, 6693, 'Levomilnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2869, 14737, 'Levomilnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2870, 22757, 'Levomilnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2871, 22758, 'Levomilnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2872, 22759, 'Levomilnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2873, 22760, 'Levomilnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2874, 22761, 'Levomilnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2875, 22762, 'Levomilnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2876, 23184, 'Levomilnacipran', 'Glaucoma', 'SNRI antidepressants cause pupillary dilation that may trigger an angle closure attack in patients with anatomically narrow angle without iridectomy.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2877, 6693, 'Levomilnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2878, 14737, 'Levomilnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2879, 22757, 'Levomilnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2880, 22758, 'Levomilnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2881, 22759, 'Levomilnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2882, 22760, 'Levomilnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2883, 22761, 'Levomilnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2884, 22762, 'Levomilnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2885, 23184, 'Levomilnacipran', 'Hypertension', 'Selective serotonin and norepinephrine reuptake inhibitor antidepressants (SNRIs) have been associated with sustained increases in blood pressure.  Therapy with SNRI antidepressants should be administered cautiously in patients with preexisting hypertension.  Blood pressure should be assessed prior to initiating treatment and monitored regularly.  The dose should be reduced or discontinued if necessary.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2886, 6693, 'Levomilnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2887, 14737, 'Levomilnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2888, 22757, 'Levomilnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2889, 22758, 'Levomilnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2890, 22759, 'Levomilnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2891, 22760, 'Levomilnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2892, 22761, 'Levomilnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2893, 22762, 'Levomilnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2894, 23184, 'Levomilnacipran', 'Hyponatremia', 'Treatment with SNRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2895, 6693, 'Levomilnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2896, 14737, 'Levomilnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2897, 22757, 'Levomilnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2898, 22758, 'Levomilnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2899, 22759, 'Levomilnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2900, 22760, 'Levomilnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2901, 22761, 'Levomilnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2902, 22762, 'Levomilnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2903, 23184, 'Levomilnacipran', 'Mania', 'Therapy with SNRI antidepressants can cause activation of mania and hypomania and should be used with caution in patients with personal or family history of mania, hypomania, bipolar disorder, and other mood disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2904, 6693, 'Levomilnacipran', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2905, 14737, 'Levomilnacipran', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2906, 22757, 'Levomilnacipran', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2907, 22758, 'Levomilnacipran', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2908, 22759, 'Levomilnacipran', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2909, 22760, 'Levomilnacipran', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2910, 22761, 'Levomilnacipran', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2911, 22762, 'Levomilnacipran', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2912, 23184, 'Levomilnacipran', 'Seizures', 'SNRI antidepressants may trigger seizures and should be administered with caution in patients with a seizure disorder.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2913, 6693, 'Levomilnacipran', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2914, 14737, 'Levomilnacipran', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2915, 22757, 'Levomilnacipran', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2916, 22758, 'Levomilnacipran', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2917, 22759, 'Levomilnacipran', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2918, 22760, 'Levomilnacipran', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2919, 22761, 'Levomilnacipran', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2920, 22762, 'Levomilnacipran', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2921, 23184, 'Levomilnacipran', 'Urethral Obstruction', 'SNRI antidepressants have a noradrenergic effect and can affect urethral resistance.  Caution should be used in patients with a history of dysuria, prostatic hypertrophy, prostatitis, and other lower urinary tract obstructive disorders.', '2', '"Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company  (2004):|"Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories  (2008):|"Product Information. Savella (milnacipran)." Forest Pharmaceuticals  (2009):|"Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2922, 16289, 'Levosalbutamol', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Larsson S "Long-term treatment with beta2-adrenostimulants in asthma. Side effects, selectivity, tolerance, and routes of administration." Acta Med Scand Suppl 608 (1977):  1-40|Mettauer B, Rouleau JL, Burgess JH "Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure." Am Heart J 109 (1985):  840-7|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Vathenen AS, Britton JR, Ebden P, Cookson JB, Wharrad HJ, Tattersfield AE "High-dose inhaled albuterol in severe chronic airflow limitation." Am Rev Respir Dis 138 (1988):  850-5|Godfrey S "Worldwide experience with albuterol (salbutamol)." Ann Allergy 47 (1981):  423-6|Finch JS "Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial." Ann Allergy 47 (1981):  402-4|Neville E, Corris PA, Vivian J, Nariman S, Gibson GJ "Nebulised salbutamol and angina." Br Med J (Clin Res Ed) 285 (1982):  796-7|Breeden CC, Safirstein BH "Albuterol and spacer-induced atrial fibrillation." Chest 98 (1990):  762-3|Wolfe JD, Yamate M, Biedermann AA, Chu TJ "Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics." JAMA 253 (1985):  2068-72|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Shovlin CL, Tam FW "Salbutamol nebuliser and precipitation of critical cardiac ischaemia." Lancet 336 (1990):  1258|Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS "The use of beta-agonists and the risk of death and near death from asthma." N Engl J Med 326 (1992):  501-6|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Richards DM, Brogden RN "Pirbuterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible bronchospastic disease." Drugs 30 (1985):  6-21|Lampert MB, Hibbard J, Weinert L, Briller J, Lindheimer M, Lang RM "Peripartum heart failure associated with prolonged tocolytic therapy." Am J Obstet Gynecol 168 (1993):  493-5|Al-Hillawi AH, Hayward R, Johnson NM "Incidence of cardiac arrhythmias in patients taking slow release salbutamol and slow release terbutaline for asthma." Br Med J (Clin Res Ed) 288 (1984):  367|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology." J Allergy Clin Immunol 75 (1985):  443-9|Wagner JM, Morton MJ, Johnson KA, O''Grady JP, Speroff L "Terbutaline and maternal cardiac function." JAMA 246 (1981):  2697-701|Kinney EL, Trautlein JJ, Harbaugh CV, Lambert D, Zelis RF "Ventricular tachycardia after terbutaline." JAMA 240 (1978):  2247|Whitsett TL, Manion CV, Wilson MF "Cardiac, pulmonary and neuromuscular effects of clenbuterol and terbutaline compared with placebo." Br J Clin Pharmacol 12 (1981):  195-200|Brogden RN, Speight TM, Avery GS "Terbutaline: a preliminary report of its pharmacological properties and therapeutic efficacy in asthma." Drugs 6 (1973):  324-32|Trautlein J, Allegra J, Gillin M "Aerosolized terbutaline sulfate--an evalution of efficacy and side effects in patients with reversible airway disease." J Clin Pharmacol 17 (1977):  76-80|Maguire GP, Emirgil C "Bronchodilator and side effects of different modes of administration of metaproterenol: inhaled, oral, and in combination." Am J Med Sci 291 (1986):  168-74|Ence TJ, Tashkin DP, Ho D, Child JS "Acute bronchial and cardiovascular effects of oral pirbuterol and metaproterenol." Ann Allergy 43 (1979):  229-36|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Brogden RN, Faulds D "Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease." Drugs 42 (1991):  895-912|Littner MR, Tashkin DP, Calvarese B, Bautista M "Acute bronchial and cardiovascular effects of increasing doses of pirbuterol acetate aerosol in asthma." Ann Allergy 48 (1982):  14-20|Chodosh S, Crooks LA, Tuck J "Comparative effects of pirbuterol acetate, metaproterenol, and placebo aerosols on pulmonary function and incidence of cardiac ectopy." J Asthma 26 (1989):  309-15|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Hibbard JU "Chronic terbutaline therapy and peripartum cardiomyopathy: a case-control study." Hypertens Pregnancy 15 (1996):  183-91|Katz M, Robertson PA, Creasy RK "Cardiovascular complications associated with terbutaline treatment for preterm labor." Am J Obstet Gynecol 139 (1981):  605-8|Suissa S, Hemmelgarn B, Blais L, Ernst P "Bronchodilators and acute cardiac death." Am J Respir Crit Care Med 154 (1996):  1598-602|Tranfa CME, Pelaia G, Grembiale RD, Naty S, Durante S, Borrello G "Short-term cardiovascular effects of salmeterol." Chest 113 (1998):  1272-6|Braden GL, Germain MJ, Mulhern JG, Hafer JG, Bria WF "Hemodynamic, cardiac, and electrolyte effects of low-dose aerosolized terbutaline sulfate in asthmatic patients." Chest 114 (1998):  380-7|Jenne JW "Can oral beta(2) agonists cause heart failure?" Lancet 352 (1998):  1081-2|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|Nathan RA, Bronsky EA, Dockhorn RJ, Kemp JP "Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma." Ann Allergy 72 (1994):  209-16|Bierman CW, Kemp JP, Nathan RA "Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma." Ann Allergy Asthma Immunol 76 (1996):  27-35|Pinnas JL, Bhatt BD, Campbell SC, Kemp JP, Tinkelman DG "Dose-response study of nebulized bitolterol mesylate solution in asthmatic patients." Chest 91 (1987):  533-9|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2923, 32641, 'Levosalbutamol', 'Cardiovascular Diseases', 'Adrenergic bronchodilators can stimulate cardiovascular beta- 1 and beta- 2 receptors, resulting in adverse effects such as tachycardia, palpitation, peripheral vasodilation, blood pressure changes, and ECG changes (e.g., flattening of the T wave; prolongation of the QT interval; ST segment depression).  Direct stimulation of cardiac tissues is mediated by beta- 1 receptors and thus less likely to occur with beta-2-selective agents such as albuterol.  However, beta-2-selectivity is not absolute and can be lost with larger doses.  High dosages of these agents have been associated with precipitation or aggravation of angina, myocardial ischemia, and cardiac arrhythmias.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, and/or underlying cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, or hypertension.  The recommended dosages should not be exceeded.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Larsson S "Long-term treatment with beta2-adrenostimulants in asthma. Side effects, selectivity, tolerance, and routes of administration." Acta Med Scand Suppl 608 (1977):  1-40|Mettauer B, Rouleau JL, Burgess JH "Detrimental arrhythmogenic and sustained beneficial hemodynamic effects of oral salbutamol in patients with chronic congestive heart failure." Am Heart J 109 (1985):  840-7|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Vathenen AS, Britton JR, Ebden P, Cookson JB, Wharrad HJ, Tattersfield AE "High-dose inhaled albuterol in severe chronic airflow limitation." Am Rev Respir Dis 138 (1988):  850-5|Godfrey S "Worldwide experience with albuterol (salbutamol)." Ann Allergy 47 (1981):  423-6|Finch JS "Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial." Ann Allergy 47 (1981):  402-4|Neville E, Corris PA, Vivian J, Nariman S, Gibson GJ "Nebulised salbutamol and angina." Br Med J (Clin Res Ed) 285 (1982):  796-7|Breeden CC, Safirstein BH "Albuterol and spacer-induced atrial fibrillation." Chest 98 (1990):  762-3|Wolfe JD, Yamate M, Biedermann AA, Chu TJ "Comparison of the acute cardiopulmonary effects of oral albuterol, metaproterenol, and terbutaline in asthmatics." JAMA 253 (1985):  2068-72|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Shovlin CL, Tam FW "Salbutamol nebuliser and precipitation of critical cardiac ischaemia." Lancet 336 (1990):  1258|Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS "The use of beta-agonists and the risk of death and near death from asthma." N Engl J Med 326 (1992):  501-6|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Richards DM, Brogden RN "Pirbuterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible bronchospastic disease." Drugs 30 (1985):  6-21|Lampert MB, Hibbard J, Weinert L, Briller J, Lindheimer M, Lang RM "Peripartum heart failure associated with prolonged tocolytic therapy." Am J Obstet Gynecol 168 (1993):  493-5|Al-Hillawi AH, Hayward R, Johnson NM "Incidence of cardiac arrhythmias in patients taking slow release salbutamol and slow release terbutaline for asthma." Br Med J (Clin Res Ed) 288 (1984):  367|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology." J Allergy Clin Immunol 75 (1985):  443-9|Wagner JM, Morton MJ, Johnson KA, O''Grady JP, Speroff L "Terbutaline and maternal cardiac function." JAMA 246 (1981):  2697-701|Kinney EL, Trautlein JJ, Harbaugh CV, Lambert D, Zelis RF "Ventricular tachycardia after terbutaline." JAMA 240 (1978):  2247|Whitsett TL, Manion CV, Wilson MF "Cardiac, pulmonary and neuromuscular effects of clenbuterol and terbutaline compared with placebo." Br J Clin Pharmacol 12 (1981):  195-200|Brogden RN, Speight TM, Avery GS "Terbutaline: a preliminary report of its pharmacological properties and therapeutic efficacy in asthma." Drugs 6 (1973):  324-32|Trautlein J, Allegra J, Gillin M "Aerosolized terbutaline sulfate--an evalution of efficacy and side effects in patients with reversible airway disease." J Clin Pharmacol 17 (1977):  76-80|Maguire GP, Emirgil C "Bronchodilator and side effects of different modes of administration of metaproterenol: inhaled, oral, and in combination." Am J Med Sci 291 (1986):  168-74|Ence TJ, Tashkin DP, Ho D, Child JS "Acute bronchial and cardiovascular effects of oral pirbuterol and metaproterenol." Ann Allergy 43 (1979):  229-36|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Brogden RN, Faulds D "Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease." Drugs 42 (1991):  895-912|Littner MR, Tashkin DP, Calvarese B, Bautista M "Acute bronchial and cardiovascular effects of increasing doses of pirbuterol acetate aerosol in asthma." Ann Allergy 48 (1982):  14-20|Chodosh S, Crooks LA, Tuck J "Comparative effects of pirbuterol acetate, metaproterenol, and placebo aerosols on pulmonary function and incidence of cardiac ectopy." J Asthma 26 (1989):  309-15|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Hibbard JU "Chronic terbutaline therapy and peripartum cardiomyopathy: a case-control study." Hypertens Pregnancy 15 (1996):  183-91|Katz M, Robertson PA, Creasy RK "Cardiovascular complications associated with terbutaline treatment for preterm labor." Am J Obstet Gynecol 139 (1981):  605-8|Suissa S, Hemmelgarn B, Blais L, Ernst P "Bronchodilators and acute cardiac death." Am J Respir Crit Care Med 154 (1996):  1598-602|Tranfa CME, Pelaia G, Grembiale RD, Naty S, Durante S, Borrello G "Short-term cardiovascular effects of salmeterol." Chest 113 (1998):  1272-6|Braden GL, Germain MJ, Mulhern JG, Hafer JG, Bria WF "Hemodynamic, cardiac, and electrolyte effects of low-dose aerosolized terbutaline sulfate in asthmatic patients." Chest 114 (1998):  380-7|Jenne JW "Can oral beta(2) agonists cause heart failure?" Lancet 352 (1998):  1081-2|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|Nathan RA, Bronsky EA, Dockhorn RJ, Kemp JP "Multicenter dose-ranging study of bitolterol mesylate solution for nebulization in children with asthma." Ann Allergy 72 (1994):  209-16|Bierman CW, Kemp JP, Nathan RA "Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma." Ann Allergy Asthma Immunol 76 (1996):  27-35|Pinnas JL, Bhatt BD, Campbell SC, Kemp JP, Tinkelman DG "Dose-response study of nebulized bitolterol mesylate solution in asthmatic patients." Chest 91 (1987):  533-9|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2924, 16289, 'Levosalbutamol', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2925, 32641, 'Levosalbutamol', 'Diabetes Mellitus', 'Adrenergic bronchodilators may cause increases in blood glucose concentrations.  These effects are usually transient and slight, but may be significant with dosages higher than those normally recommended.  Large doses of IV albuterol (not commercially available in the U.S.) and terbutaline sulfate have been reported to cause exacerbation of preexisting diabetes mellitus and ketoacidosis.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with diabetes mellitus.  Closer monitoring of blood glucose concentrations may be appropriate.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Chazan R, Droszcz W, Maruchin JE "Pharmacodynamics of salbutamol in humans." Int J Clin Pharmacol Ther Toxicol 26 (1988):  385-7|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2926, 16289, 'Levosalbutamol', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987):  65-71|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Allon M, Dunlay R, Copkney C "Nebulized albuterol for acute hyperkalemia in patients on hemodialysis." Ann Intern Med 110 (1989):  426-9|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|"Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981):  500-1|Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986):  619-20|Montoliu J, Almirall J, Ponz E, Campistol JM, Revert L "Treatment of hyperkalaemia in renal failure with salbutamol inhalation." J Intern Med 228 (1990):  35-7|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980):  1225-6|Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981):  723-5|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988):  763-6|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990):  259-61|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994):  1654-9|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997):  1867-75|Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998):  145-7|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2927, 32641, 'Levosalbutamol', 'Hypokalemia', 'Adrenergic bronchodilators may cause decreases in serum potassium concentrations, primarily when given by nebulization or intravenous administration.  Although this effect is usually transient and does not require supplementation, clinically significant hypokalemia may occur in some patients, with the potential to induce cardiovascular adverse effects.  The relevance of these observations to oral or oral aerosol/powder for inhalation therapy is unknown.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with or predisposed to hypokalemia.', '2', 'Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987):  65-71|Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Allon M, Dunlay R, Copkney C "Nebulized albuterol for acute hyperkalemia in patients on hemodialysis." Ann Intern Med 110 (1989):  426-9|Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978):  767-9|"Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981):  500-1|Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986):  619-20|Montoliu J, Almirall J, Ponz E, Campistol JM, Revert L "Treatment of hyperkalaemia in renal failure with salbutamol inhalation." J Intern Med 228 (1990):  35-7|Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990):  1396-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980):  1225-6|Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981):  723-5|Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982):  726-32|Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988):  763-6|Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977):  174-9|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|Meyer JM, Wenzel CL, Kradjan WA "Salmeterol: a novel, long-acting beta 2-agonist." Ann Pharmacother 27 (1993):  1478-87|Maconochie JG, Forster JK "Dose-response study with high-dose inhaled salmeterol in healthy subjects." Br J Clin Pharmacol 33 (1992):  342-5|Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990):  259-61|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994):  1654-9|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997):  1867-75|Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998):  145-7|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS "The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients." J Allerg Clin Immunol 103 (1999):  615-21|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2928, 16289, 'Levosalbutamol', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2929, 32641, 'Levosalbutamol', 'Seizures', 'Adrenergic bronchodilators may cause CNS stimulation.  Therapy with adrenergic bronchodilators should be administered cautiously in patients with seizure disorders.  Systemic adverse effects are minimized, but not abolished, by administration of these agents via oral inhalation.', '2', 'Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977):  861-9|Price AH, Clissold SP "Salbutamol in the 1980s. A reappraisal of its clinical efficacy." Drugs 38 (1989):  77-122|"Product Information. Proventil (albuterol)." Schering Corporation  (2002):|"Product Information. Ventolin (albuterol)." Glaxo Wellcome  (2002):|"Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals  (2001):|"Product Information. Serevent (salmeterol)." Glaxo Wellcome|"Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals  (2001):|"Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim  (2001):|"Product Information. Tornalate (bitolterol)." Apothecon Inc  (2022):|"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):|"Product Information. Foradil (formoterol)." Novartis Pharmaceuticals  (2001):|"Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim  (2014):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2930, 16289, 'Levosalbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2931, 32641, 'Levosalbutamol', 'Kidney Diseases', 'Levalbuterol is substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function.  Care should be taken in dose selection in patients with renal impairment and it may be useful to monitor renal function.', '2', '"Product Information. Xopenex (levalbuterol)." Sepracor Inc  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2932, 6419, 'Antithymocyte immunoglobulin (rabbit)', 'Infections', 'The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression.  To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use.  Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments.  It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated.  Also, total white blood cell and platelet counts should be monitored.', '3', '"Product Information. Thymoglobulin (rabbit) (anti-thymocyte globulin (rabbit))." Genzyme Corporation', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2933, 20659, 'Antithymocyte immunoglobulin (rabbit)', 'Infections', 'The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression.  To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use.  Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments.  It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated.  Also, total white blood cell and platelet counts should be monitored.', '3', '"Product Information. Thymoglobulin (rabbit) (anti-thymocyte globulin (rabbit))." Genzyme Corporation', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2934, 20660, 'Antithymocyte immunoglobulin (rabbit)', 'Infections', 'The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression.  To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use.  Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments.  It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated.  Also, total white blood cell and platelet counts should be monitored.', '3', '"Product Information. Thymoglobulin (rabbit) (anti-thymocyte globulin (rabbit))." Genzyme Corporation', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2935, 20661, 'Antithymocyte immunoglobulin (rabbit)', 'Infections', 'The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression.  To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use.  Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments.  It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated.  Also, total white blood cell and platelet counts should be monitored.', '3', '"Product Information. Thymoglobulin (rabbit) (anti-thymocyte globulin (rabbit))." Genzyme Corporation', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2936, 20662, 'Antithymocyte immunoglobulin (rabbit)', 'Infections', 'The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression.  To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use.  Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments.  It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated.  Also, total white blood cell and platelet counts should be monitored.', '3', '"Product Information. Thymoglobulin (rabbit) (anti-thymocyte globulin (rabbit))." Genzyme Corporation', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2937, 20903, 'Antithymocyte immunoglobulin (rabbit)', 'Infections', 'The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression.  To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use.  Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments.  It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated.  Also, total white blood cell and platelet counts should be monitored.', '3', '"Product Information. Thymoglobulin (rabbit) (anti-thymocyte globulin (rabbit))." Genzyme Corporation', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2938, 20904, 'Antithymocyte immunoglobulin (rabbit)', 'Infections', 'The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression.  To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use.  Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments.  It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated.  Also, total white blood cell and platelet counts should be monitored.', '3', '"Product Information. Thymoglobulin (rabbit) (anti-thymocyte globulin (rabbit))." Genzyme Corporation', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2939, 20905, 'Antithymocyte immunoglobulin (rabbit)', 'Infections', 'The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression.  To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use.  Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments.  It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated.  Also, total white blood cell and platelet counts should be monitored.', '3', '"Product Information. Thymoglobulin (rabbit) (anti-thymocyte globulin (rabbit))." Genzyme Corporation', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2940, 29800, 'Antithymocyte immunoglobulin (rabbit)', 'Infections', 'The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression.  To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use.  Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments.  It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated.  Also, total white blood cell and platelet counts should be monitored.', '3', '"Product Information. Thymoglobulin (rabbit) (anti-thymocyte globulin (rabbit))." Genzyme Corporation', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2941, 30582, 'Antithymocyte immunoglobulin (rabbit)', 'Infections', 'The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression.  To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use.  Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments.  It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated.  Also, total white blood cell and platelet counts should be monitored.', '3', '"Product Information. Thymoglobulin (rabbit) (anti-thymocyte globulin (rabbit))." Genzyme Corporation', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2942, 30583, 'Antithymocyte immunoglobulin (rabbit)', 'Infections', 'The use of anti-thymocyte globulin [rabbit] is contraindicated in patients who have active acute or chronic infections that contraindicate any additional immunosuppression.  To prevent over-immunosuppression, physicians may wish to decrease the dose of the maintenance immunosuppression regimen during the period of therapy use.  Low counts of platelets and white blood cells (including low counts of lymphocytes and neutrophils) have been identified and are reversible following dose adjustments.  It is recommended to monitor patients carefully and administer appropriate anti-infective treatment when indicated.  Also, total white blood cell and platelet counts should be monitored.', '3', '"Product Information. Thymoglobulin (rabbit) (anti-thymocyte globulin (rabbit))." Genzyme Corporation', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2943, 16758, 'Levonorgestrel', 'Abnormal Genital Bleeding', 'The use of contraceptives is contraindicated when there is an undiagnosed abnormal genital bleeding.  Adequate diagnostic measures should be undertaken to rule out the presence of any malignancy.', '3', '"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Liletta (levonorgestrel)." Actavis Pharma, Inc.  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2944, 21534, 'Levonorgestrel', 'Abnormal Genital Bleeding', 'The use of contraceptives is contraindicated when there is an undiagnosed abnormal genital bleeding.  Adequate diagnostic measures should be undertaken to rule out the presence of any malignancy.', '3', '"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Liletta (levonorgestrel)." Actavis Pharma, Inc.  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2945, 22725, 'Levonorgestrel', 'Abnormal Genital Bleeding', 'The use of contraceptives is contraindicated when there is an undiagnosed abnormal genital bleeding.  Adequate diagnostic measures should be undertaken to rule out the presence of any malignancy.', '3', '"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Liletta (levonorgestrel)." Actavis Pharma, Inc.  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2946, 22836, 'Levonorgestrel', 'Abnormal Genital Bleeding', 'The use of contraceptives is contraindicated when there is an undiagnosed abnormal genital bleeding.  Adequate diagnostic measures should be undertaken to rule out the presence of any malignancy.', '3', '"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Liletta (levonorgestrel)." Actavis Pharma, Inc.  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2947, 25073, 'Levonorgestrel', 'Abnormal Genital Bleeding', 'The use of contraceptives is contraindicated when there is an undiagnosed abnormal genital bleeding.  Adequate diagnostic measures should be undertaken to rule out the presence of any malignancy.', '3', '"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Liletta (levonorgestrel)." Actavis Pharma, Inc.  (2016):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2948, 16758, 'Levonorgestrel', 'Liver Neoplasms', 'The use of oral contraceptives is contraindicated in patients with liver tumors.  An increased risk of benign hepatic adenomas and hepatocellular carcinomas has been associated with long-term, oral estrogen- progestin contraceptive use of at least 4 years and 8 years, respectively.  Although these tumors are rare and have not been reported with other types of estrogen or progestogen therapies, any preparation containing estrogens and/or progestogens should probably be avoided in patients with existing tumors of the liver.  Hepatic hemangiomas and nodular hyperplasia of the liver have been reported with isolated estrogen therapy.', '3', 'Tao LC "Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma." Cancer 68 (1991):  341-7|"Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer.  The WHO Collaborative Study of Neoplasia and Steroid Contraceptives." Int J Cancer 49 (1991):  182-5|Conter RL, Longmire WP Jr "Recurrent hepatic hemangiomas. Possible association with estrogen therapy." Ann Surg 207 (1988):  115-9|Aldinger K, Ben-Menachem Y, Whalen G "Focal nodular hyperplasia of the liver associated with high-dosage estrogens." Arch Intern Med 137 (1977):  357-9|Palmer JR, Rosenberg L, Kaufman DW, Warshauer ME, Stolley P, Shapiro S "Oral contraceptive use and liver cancer." Am J Epidemiol 130 (1989):  878-82|Mooney MJ, Nyreen MR, Hall RA, Carter PL "Hepatic adenoma presenting as a right lower quadrant mass." Am Surg 59 (1993):  229-31|Gyorffy EJ, Bredfeldt JE, Black WC "Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use." Ann Intern Med 110 (1989):  489-90|Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C "Female hormone utilisation and risk of hepatocellular carcinoma." Br J Cancer 67 (1993):  635-7|Mathieu D, Zafrani ES, Anglade MC, Dhumeaux D "Association of focal nodular hyperplasia and hepatic hemangioma." Gastroenterology 97 (1989):  154-7|Le Bail B, Jouhanole H, Deugnier Y, Salame G, Pellegrin JL, Saric J, Balabaud C, Bioulac-Sage P "Liver adenomatosis with granulomas in two patients on long-term oral contraceptives." Am J Surg Pathol 16 (1992):  982-7|"Oral contraceptives and neoplasia. WHO Scientific Group." World Health Organ Tech Rep Ser 817 (1992):  1-46|Mishell DR "Contraception." N Engl J Med 320 (1989):  777-85|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2949, 21534, 'Levonorgestrel', 'Liver Neoplasms', 'The use of oral contraceptives is contraindicated in patients with liver tumors.  An increased risk of benign hepatic adenomas and hepatocellular carcinomas has been associated with long-term, oral estrogen- progestin contraceptive use of at least 4 years and 8 years, respectively.  Although these tumors are rare and have not been reported with other types of estrogen or progestogen therapies, any preparation containing estrogens and/or progestogens should probably be avoided in patients with existing tumors of the liver.  Hepatic hemangiomas and nodular hyperplasia of the liver have been reported with isolated estrogen therapy.', '3', 'Tao LC "Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma." Cancer 68 (1991):  341-7|"Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer.  The WHO Collaborative Study of Neoplasia and Steroid Contraceptives." Int J Cancer 49 (1991):  182-5|Conter RL, Longmire WP Jr "Recurrent hepatic hemangiomas. Possible association with estrogen therapy." Ann Surg 207 (1988):  115-9|Aldinger K, Ben-Menachem Y, Whalen G "Focal nodular hyperplasia of the liver associated with high-dosage estrogens." Arch Intern Med 137 (1977):  357-9|Palmer JR, Rosenberg L, Kaufman DW, Warshauer ME, Stolley P, Shapiro S "Oral contraceptive use and liver cancer." Am J Epidemiol 130 (1989):  878-82|Mooney MJ, Nyreen MR, Hall RA, Carter PL "Hepatic adenoma presenting as a right lower quadrant mass." Am Surg 59 (1993):  229-31|Gyorffy EJ, Bredfeldt JE, Black WC "Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use." Ann Intern Med 110 (1989):  489-90|Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C "Female hormone utilisation and risk of hepatocellular carcinoma." Br J Cancer 67 (1993):  635-7|Mathieu D, Zafrani ES, Anglade MC, Dhumeaux D "Association of focal nodular hyperplasia and hepatic hemangioma." Gastroenterology 97 (1989):  154-7|Le Bail B, Jouhanole H, Deugnier Y, Salame G, Pellegrin JL, Saric J, Balabaud C, Bioulac-Sage P "Liver adenomatosis with granulomas in two patients on long-term oral contraceptives." Am J Surg Pathol 16 (1992):  982-7|"Oral contraceptives and neoplasia. WHO Scientific Group." World Health Organ Tech Rep Ser 817 (1992):  1-46|Mishell DR "Contraception." N Engl J Med 320 (1989):  777-85|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2950, 22725, 'Levonorgestrel', 'Liver Neoplasms', 'The use of oral contraceptives is contraindicated in patients with liver tumors.  An increased risk of benign hepatic adenomas and hepatocellular carcinomas has been associated with long-term, oral estrogen- progestin contraceptive use of at least 4 years and 8 years, respectively.  Although these tumors are rare and have not been reported with other types of estrogen or progestogen therapies, any preparation containing estrogens and/or progestogens should probably be avoided in patients with existing tumors of the liver.  Hepatic hemangiomas and nodular hyperplasia of the liver have been reported with isolated estrogen therapy.', '3', 'Tao LC "Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma." Cancer 68 (1991):  341-7|"Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer.  The WHO Collaborative Study of Neoplasia and Steroid Contraceptives." Int J Cancer 49 (1991):  182-5|Conter RL, Longmire WP Jr "Recurrent hepatic hemangiomas. Possible association with estrogen therapy." Ann Surg 207 (1988):  115-9|Aldinger K, Ben-Menachem Y, Whalen G "Focal nodular hyperplasia of the liver associated with high-dosage estrogens." Arch Intern Med 137 (1977):  357-9|Palmer JR, Rosenberg L, Kaufman DW, Warshauer ME, Stolley P, Shapiro S "Oral contraceptive use and liver cancer." Am J Epidemiol 130 (1989):  878-82|Mooney MJ, Nyreen MR, Hall RA, Carter PL "Hepatic adenoma presenting as a right lower quadrant mass." Am Surg 59 (1993):  229-31|Gyorffy EJ, Bredfeldt JE, Black WC "Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use." Ann Intern Med 110 (1989):  489-90|Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C "Female hormone utilisation and risk of hepatocellular carcinoma." Br J Cancer 67 (1993):  635-7|Mathieu D, Zafrani ES, Anglade MC, Dhumeaux D "Association of focal nodular hyperplasia and hepatic hemangioma." Gastroenterology 97 (1989):  154-7|Le Bail B, Jouhanole H, Deugnier Y, Salame G, Pellegrin JL, Saric J, Balabaud C, Bioulac-Sage P "Liver adenomatosis with granulomas in two patients on long-term oral contraceptives." Am J Surg Pathol 16 (1992):  982-7|"Oral contraceptives and neoplasia. WHO Scientific Group." World Health Organ Tech Rep Ser 817 (1992):  1-46|Mishell DR "Contraception." N Engl J Med 320 (1989):  777-85|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2951, 22836, 'Levonorgestrel', 'Liver Neoplasms', 'The use of oral contraceptives is contraindicated in patients with liver tumors.  An increased risk of benign hepatic adenomas and hepatocellular carcinomas has been associated with long-term, oral estrogen- progestin contraceptive use of at least 4 years and 8 years, respectively.  Although these tumors are rare and have not been reported with other types of estrogen or progestogen therapies, any preparation containing estrogens and/or progestogens should probably be avoided in patients with existing tumors of the liver.  Hepatic hemangiomas and nodular hyperplasia of the liver have been reported with isolated estrogen therapy.', '3', 'Tao LC "Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma." Cancer 68 (1991):  341-7|"Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer.  The WHO Collaborative Study of Neoplasia and Steroid Contraceptives." Int J Cancer 49 (1991):  182-5|Conter RL, Longmire WP Jr "Recurrent hepatic hemangiomas. Possible association with estrogen therapy." Ann Surg 207 (1988):  115-9|Aldinger K, Ben-Menachem Y, Whalen G "Focal nodular hyperplasia of the liver associated with high-dosage estrogens." Arch Intern Med 137 (1977):  357-9|Palmer JR, Rosenberg L, Kaufman DW, Warshauer ME, Stolley P, Shapiro S "Oral contraceptive use and liver cancer." Am J Epidemiol 130 (1989):  878-82|Mooney MJ, Nyreen MR, Hall RA, Carter PL "Hepatic adenoma presenting as a right lower quadrant mass." Am Surg 59 (1993):  229-31|Gyorffy EJ, Bredfeldt JE, Black WC "Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use." Ann Intern Med 110 (1989):  489-90|Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C "Female hormone utilisation and risk of hepatocellular carcinoma." Br J Cancer 67 (1993):  635-7|Mathieu D, Zafrani ES, Anglade MC, Dhumeaux D "Association of focal nodular hyperplasia and hepatic hemangioma." Gastroenterology 97 (1989):  154-7|Le Bail B, Jouhanole H, Deugnier Y, Salame G, Pellegrin JL, Saric J, Balabaud C, Bioulac-Sage P "Liver adenomatosis with granulomas in two patients on long-term oral contraceptives." Am J Surg Pathol 16 (1992):  982-7|"Oral contraceptives and neoplasia. WHO Scientific Group." World Health Organ Tech Rep Ser 817 (1992):  1-46|Mishell DR "Contraception." N Engl J Med 320 (1989):  777-85|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2952, 25073, 'Levonorgestrel', 'Liver Neoplasms', 'The use of oral contraceptives is contraindicated in patients with liver tumors.  An increased risk of benign hepatic adenomas and hepatocellular carcinomas has been associated with long-term, oral estrogen- progestin contraceptive use of at least 4 years and 8 years, respectively.  Although these tumors are rare and have not been reported with other types of estrogen or progestogen therapies, any preparation containing estrogens and/or progestogens should probably be avoided in patients with existing tumors of the liver.  Hepatic hemangiomas and nodular hyperplasia of the liver have been reported with isolated estrogen therapy.', '3', 'Tao LC "Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma." Cancer 68 (1991):  341-7|"Depot-medroxyprogesterone acetate (DMPA) and risk of liver cancer.  The WHO Collaborative Study of Neoplasia and Steroid Contraceptives." Int J Cancer 49 (1991):  182-5|Conter RL, Longmire WP Jr "Recurrent hepatic hemangiomas. Possible association with estrogen therapy." Ann Surg 207 (1988):  115-9|Aldinger K, Ben-Menachem Y, Whalen G "Focal nodular hyperplasia of the liver associated with high-dosage estrogens." Arch Intern Med 137 (1977):  357-9|Palmer JR, Rosenberg L, Kaufman DW, Warshauer ME, Stolley P, Shapiro S "Oral contraceptive use and liver cancer." Am J Epidemiol 130 (1989):  878-82|Mooney MJ, Nyreen MR, Hall RA, Carter PL "Hepatic adenoma presenting as a right lower quadrant mass." Am Surg 59 (1993):  229-31|Gyorffy EJ, Bredfeldt JE, Black WC "Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use." Ann Intern Med 110 (1989):  489-90|Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C "Female hormone utilisation and risk of hepatocellular carcinoma." Br J Cancer 67 (1993):  635-7|Mathieu D, Zafrani ES, Anglade MC, Dhumeaux D "Association of focal nodular hyperplasia and hepatic hemangioma." Gastroenterology 97 (1989):  154-7|Le Bail B, Jouhanole H, Deugnier Y, Salame G, Pellegrin JL, Saric J, Balabaud C, Bioulac-Sage P "Liver adenomatosis with granulomas in two patients on long-term oral contraceptives." Am J Surg Pathol 16 (1992):  982-7|"Oral contraceptives and neoplasia. WHO Scientific Group." World Health Organ Tech Rep Ser 817 (1992):  1-46|Mishell DR "Contraception." N Engl J Med 320 (1989):  777-85|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2953, 16758, 'Levonorgestrel', 'Intracranial Hypertension', 'The use of levonorgestrel contraceptive implants is contraindicated in patients with a current or past history of idiopathic intracranial hypertension (pseudotumor cerebri, benign intracranial hypertension).  This disorder is most commonly seen in obese women of reproductive age and has been reported in users of levonorgestrel implants.  Patients who experience symptoms of this disorder (e.g., headaches associated with changing frequency, pattern, severity or persistence; visual disturbances) while on levonorgestrel therapy should be referred to a neurologist.  If the diagnosis is confirmed, the implants should be removed permanently.', '3', '"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2954, 21534, 'Levonorgestrel', 'Intracranial Hypertension', 'The use of levonorgestrel contraceptive implants is contraindicated in patients with a current or past history of idiopathic intracranial hypertension (pseudotumor cerebri, benign intracranial hypertension).  This disorder is most commonly seen in obese women of reproductive age and has been reported in users of levonorgestrel implants.  Patients who experience symptoms of this disorder (e.g., headaches associated with changing frequency, pattern, severity or persistence; visual disturbances) while on levonorgestrel therapy should be referred to a neurologist.  If the diagnosis is confirmed, the implants should be removed permanently.', '3', '"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2955, 22725, 'Levonorgestrel', 'Intracranial Hypertension', 'The use of levonorgestrel contraceptive implants is contraindicated in patients with a current or past history of idiopathic intracranial hypertension (pseudotumor cerebri, benign intracranial hypertension).  This disorder is most commonly seen in obese women of reproductive age and has been reported in users of levonorgestrel implants.  Patients who experience symptoms of this disorder (e.g., headaches associated with changing frequency, pattern, severity or persistence; visual disturbances) while on levonorgestrel therapy should be referred to a neurologist.  If the diagnosis is confirmed, the implants should be removed permanently.', '3', '"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2956, 22836, 'Levonorgestrel', 'Intracranial Hypertension', 'The use of levonorgestrel contraceptive implants is contraindicated in patients with a current or past history of idiopathic intracranial hypertension (pseudotumor cerebri, benign intracranial hypertension).  This disorder is most commonly seen in obese women of reproductive age and has been reported in users of levonorgestrel implants.  Patients who experience symptoms of this disorder (e.g., headaches associated with changing frequency, pattern, severity or persistence; visual disturbances) while on levonorgestrel therapy should be referred to a neurologist.  If the diagnosis is confirmed, the implants should be removed permanently.', '3', '"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2957, 25073, 'Levonorgestrel', 'Intracranial Hypertension', 'The use of levonorgestrel contraceptive implants is contraindicated in patients with a current or past history of idiopathic intracranial hypertension (pseudotumor cerebri, benign intracranial hypertension).  This disorder is most commonly seen in obese women of reproductive age and has been reported in users of levonorgestrel implants.  Patients who experience symptoms of this disorder (e.g., headaches associated with changing frequency, pattern, severity or persistence; visual disturbances) while on levonorgestrel therapy should be referred to a neurologist.  If the diagnosis is confirmed, the implants should be removed permanently.', '3', '"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2958, 16758, 'Levonorgestrel', 'Thromboembolism', 'The use of levonorgestrel is considered by manufacturers to be contraindicated in patients with active thrombophlebitis or thromboembolic disorders.  Some manufacturers also recommend not using progestogens in patients with a history of thromboembolic or cerebrovascular disease.  While the role of progestogens in the development of thromboembolic events associated with hormonal therapy is often unclear and thought to be secondary to that of estrogens, it may not be insignificant.  Levonorgestrel implants, specifically, have been associated with thrombophlebitis and superficial phlebitis, which were more common in the arm of insertion and sometimes related to trauma to the arm.  There have also been post-marketing reports of stroke and myocardial infarction coincident with the use of levonorgestrel implants.', '3', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2959, 21534, 'Levonorgestrel', 'Thromboembolism', 'The use of levonorgestrel is considered by manufacturers to be contraindicated in patients with active thrombophlebitis or thromboembolic disorders.  Some manufacturers also recommend not using progestogens in patients with a history of thromboembolic or cerebrovascular disease.  While the role of progestogens in the development of thromboembolic events associated with hormonal therapy is often unclear and thought to be secondary to that of estrogens, it may not be insignificant.  Levonorgestrel implants, specifically, have been associated with thrombophlebitis and superficial phlebitis, which were more common in the arm of insertion and sometimes related to trauma to the arm.  There have also been post-marketing reports of stroke and myocardial infarction coincident with the use of levonorgestrel implants.', '3', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2960, 22725, 'Levonorgestrel', 'Thromboembolism', 'The use of levonorgestrel is considered by manufacturers to be contraindicated in patients with active thrombophlebitis or thromboembolic disorders.  Some manufacturers also recommend not using progestogens in patients with a history of thromboembolic or cerebrovascular disease.  While the role of progestogens in the development of thromboembolic events associated with hormonal therapy is often unclear and thought to be secondary to that of estrogens, it may not be insignificant.  Levonorgestrel implants, specifically, have been associated with thrombophlebitis and superficial phlebitis, which were more common in the arm of insertion and sometimes related to trauma to the arm.  There have also been post-marketing reports of stroke and myocardial infarction coincident with the use of levonorgestrel implants.', '3', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2961, 22836, 'Levonorgestrel', 'Thromboembolism', 'The use of levonorgestrel is considered by manufacturers to be contraindicated in patients with active thrombophlebitis or thromboembolic disorders.  Some manufacturers also recommend not using progestogens in patients with a history of thromboembolic or cerebrovascular disease.  While the role of progestogens in the development of thromboembolic events associated with hormonal therapy is often unclear and thought to be secondary to that of estrogens, it may not be insignificant.  Levonorgestrel implants, specifically, have been associated with thrombophlebitis and superficial phlebitis, which were more common in the arm of insertion and sometimes related to trauma to the arm.  There have also been post-marketing reports of stroke and myocardial infarction coincident with the use of levonorgestrel implants.', '3', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2962, 25073, 'Levonorgestrel', 'Thromboembolism', 'The use of levonorgestrel is considered by manufacturers to be contraindicated in patients with active thrombophlebitis or thromboembolic disorders.  Some manufacturers also recommend not using progestogens in patients with a history of thromboembolic or cerebrovascular disease.  While the role of progestogens in the development of thromboembolic events associated with hormonal therapy is often unclear and thought to be secondary to that of estrogens, it may not be insignificant.  Levonorgestrel implants, specifically, have been associated with thrombophlebitis and superficial phlebitis, which were more common in the arm of insertion and sometimes related to trauma to the arm.  There have also been post-marketing reports of stroke and myocardial infarction coincident with the use of levonorgestrel implants.', '3', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2963, 16758, 'Levonorgestrel', 'Breast Neoplasms', 'The use of progestogens is considered by manufacturers to be contraindicated in patients with existing or suspected malignancy of the breast.  Some supportive data are available for medroxyprogesterone.  Specifically, medroxyprogesterone treatment may be associated with breast cancer, primarily when the drug is administered intramuscularly.  A pooled analysis of two case-control studies, one from the World Health Organization and the other from New Zealand, revealed a small overall relative risk of breast cancer in women who have ever used intramuscular medroxyprogesterone acetate.  The relative risk was higher in the subgroup of women who had initiated therapy within the previous 5 years.  Thus, an increased risk (approximately 2-fold) is associated with intramuscular medroxyprogesterone use in the first 5 years.  A more recent U.S. study also found a statistically significant increase in breast cancer risk among recent users (defined as last use within the past five years) who used depo-medroxyprogesterone acetate for 12 months or longer.', '3', 'Liang AP, Levenson AG, Layde PM, Shelton JD, Hatcher RA, Potts M, Michelson MJ "Risk of breast, uterine corpus, and ovarian cancer in women receiving  medroxyprogesterone injections." JAMA 249 (1983):  2909-12|"Breast cancer, cervical cancer, and depot medroxyprogesterone  acetate. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 2 (1984):  1207-8|"Breast cancer and depot-medroxyprogesterone acetate: a multinational  study. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 338 (1991):  833-8|Jordan A "Toxicology of depot medroxyprogesterone acetate." Contraception 49 (1994):  189-201|Chilvers C "Breast cancer and depot-medroxyprogesterone acetate - a review." Contraception 49 (1994):  211-22|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|Skegg DC, Noonan EA, Paul C, Spears GF, Meirik O, Thomas DB "Depot medroxyprogesterone acetate and breast cancer." JAMA 273 (1995):  799-807|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2964, 21534, 'Levonorgestrel', 'Breast Neoplasms', 'The use of progestogens is considered by manufacturers to be contraindicated in patients with existing or suspected malignancy of the breast.  Some supportive data are available for medroxyprogesterone.  Specifically, medroxyprogesterone treatment may be associated with breast cancer, primarily when the drug is administered intramuscularly.  A pooled analysis of two case-control studies, one from the World Health Organization and the other from New Zealand, revealed a small overall relative risk of breast cancer in women who have ever used intramuscular medroxyprogesterone acetate.  The relative risk was higher in the subgroup of women who had initiated therapy within the previous 5 years.  Thus, an increased risk (approximately 2-fold) is associated with intramuscular medroxyprogesterone use in the first 5 years.  A more recent U.S. study also found a statistically significant increase in breast cancer risk among recent users (defined as last use within the past five years) who used depo-medroxyprogesterone acetate for 12 months or longer.', '3', 'Liang AP, Levenson AG, Layde PM, Shelton JD, Hatcher RA, Potts M, Michelson MJ "Risk of breast, uterine corpus, and ovarian cancer in women receiving  medroxyprogesterone injections." JAMA 249 (1983):  2909-12|"Breast cancer, cervical cancer, and depot medroxyprogesterone  acetate. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 2 (1984):  1207-8|"Breast cancer and depot-medroxyprogesterone acetate: a multinational  study. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 338 (1991):  833-8|Jordan A "Toxicology of depot medroxyprogesterone acetate." Contraception 49 (1994):  189-201|Chilvers C "Breast cancer and depot-medroxyprogesterone acetate - a review." Contraception 49 (1994):  211-22|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|Skegg DC, Noonan EA, Paul C, Spears GF, Meirik O, Thomas DB "Depot medroxyprogesterone acetate and breast cancer." JAMA 273 (1995):  799-807|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2965, 22725, 'Levonorgestrel', 'Breast Neoplasms', 'The use of progestogens is considered by manufacturers to be contraindicated in patients with existing or suspected malignancy of the breast.  Some supportive data are available for medroxyprogesterone.  Specifically, medroxyprogesterone treatment may be associated with breast cancer, primarily when the drug is administered intramuscularly.  A pooled analysis of two case-control studies, one from the World Health Organization and the other from New Zealand, revealed a small overall relative risk of breast cancer in women who have ever used intramuscular medroxyprogesterone acetate.  The relative risk was higher in the subgroup of women who had initiated therapy within the previous 5 years.  Thus, an increased risk (approximately 2-fold) is associated with intramuscular medroxyprogesterone use in the first 5 years.  A more recent U.S. study also found a statistically significant increase in breast cancer risk among recent users (defined as last use within the past five years) who used depo-medroxyprogesterone acetate for 12 months or longer.', '3', 'Liang AP, Levenson AG, Layde PM, Shelton JD, Hatcher RA, Potts M, Michelson MJ "Risk of breast, uterine corpus, and ovarian cancer in women receiving  medroxyprogesterone injections." JAMA 249 (1983):  2909-12|"Breast cancer, cervical cancer, and depot medroxyprogesterone  acetate. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 2 (1984):  1207-8|"Breast cancer and depot-medroxyprogesterone acetate: a multinational  study. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 338 (1991):  833-8|Jordan A "Toxicology of depot medroxyprogesterone acetate." Contraception 49 (1994):  189-201|Chilvers C "Breast cancer and depot-medroxyprogesterone acetate - a review." Contraception 49 (1994):  211-22|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|Skegg DC, Noonan EA, Paul C, Spears GF, Meirik O, Thomas DB "Depot medroxyprogesterone acetate and breast cancer." JAMA 273 (1995):  799-807|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2966, 22836, 'Levonorgestrel', 'Breast Neoplasms', 'The use of progestogens is considered by manufacturers to be contraindicated in patients with existing or suspected malignancy of the breast.  Some supportive data are available for medroxyprogesterone.  Specifically, medroxyprogesterone treatment may be associated with breast cancer, primarily when the drug is administered intramuscularly.  A pooled analysis of two case-control studies, one from the World Health Organization and the other from New Zealand, revealed a small overall relative risk of breast cancer in women who have ever used intramuscular medroxyprogesterone acetate.  The relative risk was higher in the subgroup of women who had initiated therapy within the previous 5 years.  Thus, an increased risk (approximately 2-fold) is associated with intramuscular medroxyprogesterone use in the first 5 years.  A more recent U.S. study also found a statistically significant increase in breast cancer risk among recent users (defined as last use within the past five years) who used depo-medroxyprogesterone acetate for 12 months or longer.', '3', 'Liang AP, Levenson AG, Layde PM, Shelton JD, Hatcher RA, Potts M, Michelson MJ "Risk of breast, uterine corpus, and ovarian cancer in women receiving  medroxyprogesterone injections." JAMA 249 (1983):  2909-12|"Breast cancer, cervical cancer, and depot medroxyprogesterone  acetate. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 2 (1984):  1207-8|"Breast cancer and depot-medroxyprogesterone acetate: a multinational  study. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 338 (1991):  833-8|Jordan A "Toxicology of depot medroxyprogesterone acetate." Contraception 49 (1994):  189-201|Chilvers C "Breast cancer and depot-medroxyprogesterone acetate - a review." Contraception 49 (1994):  211-22|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|Skegg DC, Noonan EA, Paul C, Spears GF, Meirik O, Thomas DB "Depot medroxyprogesterone acetate and breast cancer." JAMA 273 (1995):  799-807|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2967, 25073, 'Levonorgestrel', 'Breast Neoplasms', 'The use of progestogens is considered by manufacturers to be contraindicated in patients with existing or suspected malignancy of the breast.  Some supportive data are available for medroxyprogesterone.  Specifically, medroxyprogesterone treatment may be associated with breast cancer, primarily when the drug is administered intramuscularly.  A pooled analysis of two case-control studies, one from the World Health Organization and the other from New Zealand, revealed a small overall relative risk of breast cancer in women who have ever used intramuscular medroxyprogesterone acetate.  The relative risk was higher in the subgroup of women who had initiated therapy within the previous 5 years.  Thus, an increased risk (approximately 2-fold) is associated with intramuscular medroxyprogesterone use in the first 5 years.  A more recent U.S. study also found a statistically significant increase in breast cancer risk among recent users (defined as last use within the past five years) who used depo-medroxyprogesterone acetate for 12 months or longer.', '3', 'Liang AP, Levenson AG, Layde PM, Shelton JD, Hatcher RA, Potts M, Michelson MJ "Risk of breast, uterine corpus, and ovarian cancer in women receiving  medroxyprogesterone injections." JAMA 249 (1983):  2909-12|"Breast cancer, cervical cancer, and depot medroxyprogesterone  acetate. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 2 (1984):  1207-8|"Breast cancer and depot-medroxyprogesterone acetate: a multinational  study. WHO Collaborative Study of Neoplasia and Steroid  Contraceptives" Lancet 338 (1991):  833-8|Jordan A "Toxicology of depot medroxyprogesterone acetate." Contraception 49 (1994):  189-201|Chilvers C "Breast cancer and depot-medroxyprogesterone acetate - a review." Contraception 49 (1994):  211-22|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|Skegg DC, Noonan EA, Paul C, Spears GF, Meirik O, Thomas DB "Depot medroxyprogesterone acetate and breast cancer." JAMA 273 (1995):  799-807|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2968, 16758, 'Levonorgestrel', 'Liver Diseases', 'The use of progestogens, in general, is contraindicated in patients with impaired hepatic function or liver disease.  There are little or no data concerning the pharmacokinetic disposition of the different progestogens in patients with hepatic disease.  However, most hormones, including progestational hormones, are known to be extensively metabolized by the liver.  Medroxyprogesterone should not be used by women with significant liver disease and should be discontinued if jaundice or disturbances of liver function occur.', '3', 'Utaaker E, Lundgren S, Kvinnsland S, Aakvaag A "Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer." J Steroid Biochem 31 (1988):  437-41|Castegnaro E, Sala G "Pharmacokinetics and metabolism of medroxyprogesterone acetate. Influence of the route of administration and of its physical state." Steroidologia 2 (1971):  13-26|Riippa P, Kauppila A, Sundstrom H, Vihko R "Hepatic impairment during simultaneous administration of  medroxyprogesterone acetate and tamoxifen in the treatment of  endometrial and ovarian carcinoma." Anticancer Res 4 (1984):  109-12|Meyer WJ, 3d  Wiener I, Emory LE, Cole CM, Isenberg N, Fagan CJ, Thompson JC "Cholelithiasis associated with medroxyprogesterone acetate therapy in  men." Res Commun Chem Pathol Pharmacol 75 (1992):  69-84|Hendeles SM, Galand N, Schwers J "Metabolism of orally administered D-norgestrel in women." Acta Endocrinol (Copenh) 71 (1972):  557-68|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2969, 21534, 'Levonorgestrel', 'Liver Diseases', 'The use of progestogens, in general, is contraindicated in patients with impaired hepatic function or liver disease.  There are little or no data concerning the pharmacokinetic disposition of the different progestogens in patients with hepatic disease.  However, most hormones, including progestational hormones, are known to be extensively metabolized by the liver.  Medroxyprogesterone should not be used by women with significant liver disease and should be discontinued if jaundice or disturbances of liver function occur.', '3', 'Utaaker E, Lundgren S, Kvinnsland S, Aakvaag A "Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer." J Steroid Biochem 31 (1988):  437-41|Castegnaro E, Sala G "Pharmacokinetics and metabolism of medroxyprogesterone acetate. Influence of the route of administration and of its physical state." Steroidologia 2 (1971):  13-26|Riippa P, Kauppila A, Sundstrom H, Vihko R "Hepatic impairment during simultaneous administration of  medroxyprogesterone acetate and tamoxifen in the treatment of  endometrial and ovarian carcinoma." Anticancer Res 4 (1984):  109-12|Meyer WJ, 3d  Wiener I, Emory LE, Cole CM, Isenberg N, Fagan CJ, Thompson JC "Cholelithiasis associated with medroxyprogesterone acetate therapy in  men." Res Commun Chem Pathol Pharmacol 75 (1992):  69-84|Hendeles SM, Galand N, Schwers J "Metabolism of orally administered D-norgestrel in women." Acta Endocrinol (Copenh) 71 (1972):  557-68|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2970, 22725, 'Levonorgestrel', 'Liver Diseases', 'The use of progestogens, in general, is contraindicated in patients with impaired hepatic function or liver disease.  There are little or no data concerning the pharmacokinetic disposition of the different progestogens in patients with hepatic disease.  However, most hormones, including progestational hormones, are known to be extensively metabolized by the liver.  Medroxyprogesterone should not be used by women with significant liver disease and should be discontinued if jaundice or disturbances of liver function occur.', '3', 'Utaaker E, Lundgren S, Kvinnsland S, Aakvaag A "Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer." J Steroid Biochem 31 (1988):  437-41|Castegnaro E, Sala G "Pharmacokinetics and metabolism of medroxyprogesterone acetate. Influence of the route of administration and of its physical state." Steroidologia 2 (1971):  13-26|Riippa P, Kauppila A, Sundstrom H, Vihko R "Hepatic impairment during simultaneous administration of  medroxyprogesterone acetate and tamoxifen in the treatment of  endometrial and ovarian carcinoma." Anticancer Res 4 (1984):  109-12|Meyer WJ, 3d  Wiener I, Emory LE, Cole CM, Isenberg N, Fagan CJ, Thompson JC "Cholelithiasis associated with medroxyprogesterone acetate therapy in  men." Res Commun Chem Pathol Pharmacol 75 (1992):  69-84|Hendeles SM, Galand N, Schwers J "Metabolism of orally administered D-norgestrel in women." Acta Endocrinol (Copenh) 71 (1972):  557-68|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2971, 22836, 'Levonorgestrel', 'Liver Diseases', 'The use of progestogens, in general, is contraindicated in patients with impaired hepatic function or liver disease.  There are little or no data concerning the pharmacokinetic disposition of the different progestogens in patients with hepatic disease.  However, most hormones, including progestational hormones, are known to be extensively metabolized by the liver.  Medroxyprogesterone should not be used by women with significant liver disease and should be discontinued if jaundice or disturbances of liver function occur.', '3', 'Utaaker E, Lundgren S, Kvinnsland S, Aakvaag A "Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer." J Steroid Biochem 31 (1988):  437-41|Castegnaro E, Sala G "Pharmacokinetics and metabolism of medroxyprogesterone acetate. Influence of the route of administration and of its physical state." Steroidologia 2 (1971):  13-26|Riippa P, Kauppila A, Sundstrom H, Vihko R "Hepatic impairment during simultaneous administration of  medroxyprogesterone acetate and tamoxifen in the treatment of  endometrial and ovarian carcinoma." Anticancer Res 4 (1984):  109-12|Meyer WJ, 3d  Wiener I, Emory LE, Cole CM, Isenberg N, Fagan CJ, Thompson JC "Cholelithiasis associated with medroxyprogesterone acetate therapy in  men." Res Commun Chem Pathol Pharmacol 75 (1992):  69-84|Hendeles SM, Galand N, Schwers J "Metabolism of orally administered D-norgestrel in women." Acta Endocrinol (Copenh) 71 (1972):  557-68|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2972, 25073, 'Levonorgestrel', 'Liver Diseases', 'The use of progestogens, in general, is contraindicated in patients with impaired hepatic function or liver disease.  There are little or no data concerning the pharmacokinetic disposition of the different progestogens in patients with hepatic disease.  However, most hormones, including progestational hormones, are known to be extensively metabolized by the liver.  Medroxyprogesterone should not be used by women with significant liver disease and should be discontinued if jaundice or disturbances of liver function occur.', '3', 'Utaaker E, Lundgren S, Kvinnsland S, Aakvaag A "Pharmacokinetics and metabolism of medroxyprogesterone acetate in patients with advanced breast cancer." J Steroid Biochem 31 (1988):  437-41|Castegnaro E, Sala G "Pharmacokinetics and metabolism of medroxyprogesterone acetate. Influence of the route of administration and of its physical state." Steroidologia 2 (1971):  13-26|Riippa P, Kauppila A, Sundstrom H, Vihko R "Hepatic impairment during simultaneous administration of  medroxyprogesterone acetate and tamoxifen in the treatment of  endometrial and ovarian carcinoma." Anticancer Res 4 (1984):  109-12|Meyer WJ, 3d  Wiener I, Emory LE, Cole CM, Isenberg N, Fagan CJ, Thompson JC "Cholelithiasis associated with medroxyprogesterone acetate therapy in  men." Res Commun Chem Pathol Pharmacol 75 (1992):  69-84|Hendeles SM, Galand N, Schwers J "Metabolism of orally administered D-norgestrel in women." Acta Endocrinol (Copenh) 71 (1972):  557-68|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2973, 16758, 'Levonorgestrel', 'Depressive Disorder', 'The use of oral contraceptives has been associated with an increased incidence of depression.  It is uncertain whether this effect is related to the estrogenic or the progestogenic component of the contraceptive, although excess progesterone activity is associated with depression.  Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely.  The manufacturer of medroxyprogesterone recommends monitoring patients who have a history of depression and to not re- administer medroxyprogesterone if depression recurs.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2974, 21534, 'Levonorgestrel', 'Depressive Disorder', 'The use of oral contraceptives has been associated with an increased incidence of depression.  It is uncertain whether this effect is related to the estrogenic or the progestogenic component of the contraceptive, although excess progesterone activity is associated with depression.  Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely.  The manufacturer of medroxyprogesterone recommends monitoring patients who have a history of depression and to not re- administer medroxyprogesterone if depression recurs.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2975, 22725, 'Levonorgestrel', 'Depressive Disorder', 'The use of oral contraceptives has been associated with an increased incidence of depression.  It is uncertain whether this effect is related to the estrogenic or the progestogenic component of the contraceptive, although excess progesterone activity is associated with depression.  Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely.  The manufacturer of medroxyprogesterone recommends monitoring patients who have a history of depression and to not re- administer medroxyprogesterone if depression recurs.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2976, 22836, 'Levonorgestrel', 'Depressive Disorder', 'The use of oral contraceptives has been associated with an increased incidence of depression.  It is uncertain whether this effect is related to the estrogenic or the progestogenic component of the contraceptive, although excess progesterone activity is associated with depression.  Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely.  The manufacturer of medroxyprogesterone recommends monitoring patients who have a history of depression and to not re- administer medroxyprogesterone if depression recurs.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2977, 25073, 'Levonorgestrel', 'Depressive Disorder', 'The use of oral contraceptives has been associated with an increased incidence of depression.  It is uncertain whether this effect is related to the estrogenic or the progestogenic component of the contraceptive, although excess progesterone activity is associated with depression.  Patients with a history of depression receiving estrogen and/or progestogen therapy should be followed closely.  The manufacturer of medroxyprogesterone recommends monitoring patients who have a history of depression and to not re- administer medroxyprogesterone if depression recurs.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2978, 16758, 'Levonorgestrel', 'Water-Electrolyte Imbalance', 'Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid.  In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.', '2', 'Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect  on weight and blood pressure." Am J Obstet Gynecol 114 (1972):  97-102|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2979, 21534, 'Levonorgestrel', 'Water-Electrolyte Imbalance', 'Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid.  In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.', '2', 'Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect  on weight and blood pressure." Am J Obstet Gynecol 114 (1972):  97-102|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2980, 22725, 'Levonorgestrel', 'Water-Electrolyte Imbalance', 'Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid.  In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.', '2', 'Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect  on weight and blood pressure." Am J Obstet Gynecol 114 (1972):  97-102|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2981, 22836, 'Levonorgestrel', 'Water-Electrolyte Imbalance', 'Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid.  In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.', '2', 'Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect  on weight and blood pressure." Am J Obstet Gynecol 114 (1972):  97-102|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2982, 25073, 'Levonorgestrel', 'Water-Electrolyte Imbalance', 'Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid.  In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.', '2', 'Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect  on weight and blood pressure." Am J Obstet Gynecol 114 (1972):  97-102|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Megace (megestrol)." Bristol-Myers Squibb  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals  (2006):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2983, 16758, 'Levonorgestrel', 'Glucose Intolerance', 'Impaired glucose tolerance has been observed in some patients administered oral contraceptives and appears to be related primarily to the estrogen dose.  However, progestogens can increase insulin secretion and produce insulin resistance to varying degrees, depending on the agent.  Patients with diabetes mellitus should be monitored more closely during therapy with estrogens and/or progestogens, and adjustments made accordingly in their antidiabetic regimen.', '2', 'Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters." Contraception 39 (1989):  619-32|Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986):  291-6|Who Task Force on Long-acting Agents for Fertility Regulation "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ 64 (1986):  587-94|Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE "Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus." JAMA 271 (1994):  1099-102|Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989):  1315-6|Stubblefield PG "Choosing the best oral contraceptive." Clin Obstet Gynecol 32 (1989):  316-28|Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989):  71-4|Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989):  219-28|Derman R "Oral contraceptives: a reassessment." Obstet Gynecol Surv 44 (1989):  662-8|Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med 38 (1993):  207-14|Kaunitz AM "Long-acting injectable contraception with depot medroxyprogesterone acetate." Am J Obstet Gynecol 170 (1994):  1543-9|Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994):  1062-71|"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2984, 21534, 'Levonorgestrel', 'Glucose Intolerance', 'Impaired glucose tolerance has been observed in some patients administered oral contraceptives and appears to be related primarily to the estrogen dose.  However, progestogens can increase insulin secretion and produce insulin resistance to varying degrees, depending on the agent.  Patients with diabetes mellitus should be monitored more closely during therapy with estrogens and/or progestogens, and adjustments made accordingly in their antidiabetic regimen.', '2', 'Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters." Contraception 39 (1989):  619-32|Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986):  291-6|Who Task Force on Long-acting Agents for Fertility Regulation "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ 64 (1986):  587-94|Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE "Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus." JAMA 271 (1994):  1099-102|Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989):  1315-6|Stubblefield PG "Choosing the best oral contraceptive." Clin Obstet Gynecol 32 (1989):  316-28|Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989):  71-4|Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989):  219-28|Derman R "Oral contraceptives: a reassessment." Obstet Gynecol Surv 44 (1989):  662-8|Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med 38 (1993):  207-14|Kaunitz AM "Long-acting injectable contraception with depot medroxyprogesterone acetate." Am J Obstet Gynecol 170 (1994):  1543-9|Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994):  1062-71|"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2985, 22725, 'Levonorgestrel', 'Glucose Intolerance', 'Impaired glucose tolerance has been observed in some patients administered oral contraceptives and appears to be related primarily to the estrogen dose.  However, progestogens can increase insulin secretion and produce insulin resistance to varying degrees, depending on the agent.  Patients with diabetes mellitus should be monitored more closely during therapy with estrogens and/or progestogens, and adjustments made accordingly in their antidiabetic regimen.', '2', 'Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters." Contraception 39 (1989):  619-32|Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986):  291-6|Who Task Force on Long-acting Agents for Fertility Regulation "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ 64 (1986):  587-94|Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE "Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus." JAMA 271 (1994):  1099-102|Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989):  1315-6|Stubblefield PG "Choosing the best oral contraceptive." Clin Obstet Gynecol 32 (1989):  316-28|Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989):  71-4|Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989):  219-28|Derman R "Oral contraceptives: a reassessment." Obstet Gynecol Surv 44 (1989):  662-8|Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med 38 (1993):  207-14|Kaunitz AM "Long-acting injectable contraception with depot medroxyprogesterone acetate." Am J Obstet Gynecol 170 (1994):  1543-9|Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994):  1062-71|"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2986, 22836, 'Levonorgestrel', 'Glucose Intolerance', 'Impaired glucose tolerance has been observed in some patients administered oral contraceptives and appears to be related primarily to the estrogen dose.  However, progestogens can increase insulin secretion and produce insulin resistance to varying degrees, depending on the agent.  Patients with diabetes mellitus should be monitored more closely during therapy with estrogens and/or progestogens, and adjustments made accordingly in their antidiabetic regimen.', '2', 'Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters." Contraception 39 (1989):  619-32|Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986):  291-6|Who Task Force on Long-acting Agents for Fertility Regulation "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ 64 (1986):  587-94|Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE "Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus." JAMA 271 (1994):  1099-102|Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989):  1315-6|Stubblefield PG "Choosing the best oral contraceptive." Clin Obstet Gynecol 32 (1989):  316-28|Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989):  71-4|Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989):  219-28|Derman R "Oral contraceptives: a reassessment." Obstet Gynecol Surv 44 (1989):  662-8|Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med 38 (1993):  207-14|Kaunitz AM "Long-acting injectable contraception with depot medroxyprogesterone acetate." Am J Obstet Gynecol 170 (1994):  1543-9|Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994):  1062-71|"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2987, 25073, 'Levonorgestrel', 'Glucose Intolerance', 'Impaired glucose tolerance has been observed in some patients administered oral contraceptives and appears to be related primarily to the estrogen dose.  However, progestogens can increase insulin secretion and produce insulin resistance to varying degrees, depending on the agent.  Patients with diabetes mellitus should be monitored more closely during therapy with estrogens and/or progestogens, and adjustments made accordingly in their antidiabetic regimen.', '2', 'Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters." Contraception 39 (1989):  619-32|Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986):  291-6|Who Task Force on Long-acting Agents for Fertility Regulation "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ 64 (1986):  587-94|Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE "Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus." JAMA 271 (1994):  1099-102|Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989):  1315-6|Stubblefield PG "Choosing the best oral contraceptive." Clin Obstet Gynecol 32 (1989):  316-28|Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989):  71-4|Steinberg WM "Oral contraception: risks and benefits." Adv Contracept 5 (1989):  219-28|Derman R "Oral contraceptives: a reassessment." Obstet Gynecol Surv 44 (1989):  662-8|Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med 38 (1993):  207-14|Kaunitz AM "Long-acting injectable contraception with depot medroxyprogesterone acetate." Am J Obstet Gynecol 170 (1994):  1543-9|Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994):  1062-71|"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2988, 16758, 'Levonorgestrel', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', '"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2989, 21534, 'Levonorgestrel', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', '"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2990, 22725, 'Levonorgestrel', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', '"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2991, 22836, 'Levonorgestrel', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', '"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2992, 25073, 'Levonorgestrel', 'Eye Diseases', 'Estrogens and progestogens may cause retinal thrombosis.  Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions.  Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted.  Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.', '2', '"Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2993, 16758, 'Levonorgestrel', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2994, 21534, 'Levonorgestrel', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2995, 22725, 'Levonorgestrel', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2996, 22836, 'Levonorgestrel', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2997, 25073, 'Levonorgestrel', 'Thyroid Diseases', 'When administering estrogen and/or progestogen therapy in patients with thyroid disorders, clinicians should be aware that these hormones may affect thyroid function tests.  Changes have mostly been reported with the use of combination oral contraceptives.  Specifically, thyroid-binding globulin (TBG) may be increased, resulting in elevated circulating total thyroid hormone, as measured by PBI (protein-bound iodine), T4 by column or radioimmunoassay, or T3 by radioimmunoassay.  Free T3 resin uptake may be decreased.  On the contrary, a decrease in TBG and, consequently, thyroxine concentration, has been reported by the manufacturers of the progestin-only (norethindrone) oral contraceptives.', '2', '"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Deltasone (prednisone)." Pharmacia and Upjohn  (2001):|"Product Information. Climara (estradiol)." Berlex Laboratories  (2001):|"Product Information. Estrace (estradiol)." Warner Chilcott Laboratories  (2001):|"Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Emcyt (estramustine)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical|"Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn  (2001):|"Product Information. Estinyl (ethinyl estradiol)." Schering Corporation|"Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma  (2021):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2998, 16758, 'Levonorgestrel', 'Hyperlipidemias', 'Some progestogenic agents may elevate plasma LDL levels and/or lower HDL levels, although data have been inconsistent.  Patients with preexisting hyperlipidemia may require closer monitoring during progestogen therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Barnes RB, Roy S, Lobo RA "Comparison of lipid and androgen levels after conjugated estrogen or  depo-medroxyprogesterone acetate treatment in postmenopausal women." Obstet Gynecol 66 (1985):  216-9|Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters." Contraception 39 (1989):  619-32|Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986):  291-6|Teichmann AT, Wander HE, Cremer P, et al. "Medroxyprogesterone acetate and lipid metabolic changes." Arzneimittelforschung 37 (1987):  573-77|Who Task Force on Long-acting Agents for Fertility Regulation "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ 64 (1986):  587-94|Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med 38 (1993):  207-14|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (2999, 21534, 'Levonorgestrel', 'Hyperlipidemias', 'Some progestogenic agents may elevate plasma LDL levels and/or lower HDL levels, although data have been inconsistent.  Patients with preexisting hyperlipidemia may require closer monitoring during progestogen therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Barnes RB, Roy S, Lobo RA "Comparison of lipid and androgen levels after conjugated estrogen or  depo-medroxyprogesterone acetate treatment in postmenopausal women." Obstet Gynecol 66 (1985):  216-9|Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters." Contraception 39 (1989):  619-32|Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986):  291-6|Teichmann AT, Wander HE, Cremer P, et al. "Medroxyprogesterone acetate and lipid metabolic changes." Arzneimittelforschung 37 (1987):  573-77|Who Task Force on Long-acting Agents for Fertility Regulation "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ 64 (1986):  587-94|Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med 38 (1993):  207-14|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR REPLACE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (3000, 22725, 'Levonorgestrel', 'Hyperlipidemias', 'Some progestogenic agents may elevate plasma LDL levels and/or lower HDL levels, although data have been inconsistent.  Patients with preexisting hyperlipidemia may require closer monitoring during progestogen therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'Barnes RB, Roy S, Lobo RA "Comparison of lipid and androgen levels after conjugated estrogen or  depo-medroxyprogesterone acetate treatment in postmenopausal women." Obstet Gynecol 66 (1985):  216-9|Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and  their effects on some metabolic parameters." Contraception 39 (1989):  619-32|Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term  users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986):  291-6|Teichmann AT, Wander HE, Cremer P, et al. "Medroxyprogesterone acetate and lipid metabolic changes." Arzneimittelforschung 37 (1987):  573-77|Who Task Force on Long-acting Agents for Fertility Regulation "Metabolic side-effects of injectable depot-medroxyprogesterone acetate, 150 mg three-monthly, in undernourished lactating women." Bull World Health Organ 64 (1986):  587-94|Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV "Evaluation of low-dose estrogen and progestin therapy in postmenopausal women." J Reprod Med 38 (1993):  207-14|"Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn  (2001):|"Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical|"Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle|"Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical  (2001):|"Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);